[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5447
1. Rittié L, Kansra S, Stoll SW, Li Y, Gudjonsson JE, Shao Y, Michael LE, Fisher GJ, Johnson TM, Elder JT: Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin. Am J Pathol; 2007 Jun;170(6):2089-99
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin.
  • In this study, we examined ErbB1 signaling in human basal and squamous cell carcinomas (BCC and SCC) of the skin in vivo.
  • We used enzyme-linked immunosorbent assay, laser capture microdissection-coupled real-time reverse transcriptase-polymerase chain reaction, and immunohistochemistry to assess expression and activation levels of ErbB1 protein, ligands, and potential downstream effectors, in BCC and SCC tumors, stroma, and adjacent epidermis.
  • Although total ErbB1 protein and mRNA were similar in cancerous and normal skin, we found that ErbB1 activation (phospho-Tyr(1068)) was greater in bulk SCC versus BCC or normal skin.
  • In addition, three ErbB1 ligand transcripts (amphiregulin, heparin-binding epidermal growth factor-like growth factor, and transforming growth factor-alpha) were up-regulated in tumor cells of SCC but not BCC.
  • Expression of these ligands was also increased in asymptomatic epidermis adjacent to both SCC and BCC, relative to normal skin.
  • Consistently, downstream ErbB1 effectors (Erk1/2 and Akt) were activated in tumor cells of SCC but not of BCC and in adjacent epidermis of both BCC and SCC.
  • These results demonstrate that ErbB1 signaling is hyperactive in tumor cells of SCC but not of BCC and in nearby asymptomatic epidermis of both tumor types.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dermatol Surg Oncol. 1991 Jan;17(1):20-4 [1991877.001]
  • [Cites] J Invest Dermatol. 1991 Mar;96(3):328-32 [2002254.001]
  • [Cites] Arch Dermatol. 1991 Aug;127(8):1167-71 [1863074.001]
  • [Cites] Br J Dermatol. 1992 Feb;126(2):154-60 [1371396.001]
  • [Cites] J Cutan Pathol. 1992 Feb;19(1):66-72 [1556270.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1273-8 [1377811.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):643-53 [1519669.001]
  • [Cites] Br J Dermatol. 1993 Jun;128(6):644-9 [7687854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6786-90 [7688128.001]
  • [Cites] Genes Dev. 1994 Feb 15;8(4):399-413 [8125255.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):283-96 [7516410.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):44-50 [7615975.001]
  • [Cites] Science. 1995 Jul 14;269(5221):230-4 [7618084.001]
  • [Cites] Science. 1995 Jul 14;269(5221):234-8 [7618085.001]
  • [Cites] Nature. 1995 Jul 27;376(6538):337-41 [7630400.001]
  • [Cites] Clin Exp Dermatol. 1995 May;20(3):208-12 [7671414.001]
  • [Cites] EMBO J. 1995 Nov 1;14(21):5216-23 [7489711.001]
  • [Cites] Am J Dermatopathol. 1996 Apr;18(2):165-71 [8739992.001]
  • [Cites] Clin Dermatol. 1995 Nov-Dec;13(6):527-36 [8882763.001]
  • [Cites] Oncogene. 1997 Mar 27;14(12):1435-44 [9136987.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2581-5 [9205058.001]
  • [Cites] Br J Dermatol. 1997 Jun;136(6):908-12 [9217824.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):3055-62 [9230222.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3180-8 [9242447.001]
  • [Cites] Chin Med Sci J. 1996 Jun;11(2):106-9 [9387420.001]
  • [Cites] Histochem J. 1997 Oct;29(10):735-44 [9429077.001]
  • [Cites] Mol Carcinog. 1998 Jan;21(1):2-12 [9473766.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1432-40 [9502786.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):184-9 [10209149.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3593-607 [10380881.001]
  • [Cites] Neoplasma. 2000;47(3):137-42 [11043834.001]
  • [Cites] Cell Mol Life Sci. 2000 Nov;57(12):1672-81 [11130174.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):330-8 [11180011.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):461-6 [11179472.001]
  • [Cites] Dermatology. 2001;202(3):203-6 [11385224.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):26349-56 [11320083.001]
  • [Cites] Neoplasia. 2001 Jul-Aug;3(4):339-50 [11571634.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8 [11597398.001]
  • [Cites] Exp Cell Res. 2001 Dec 10;271(2):315-28 [11716544.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):26839-45 [12016209.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):756-60 [12610629.001]
  • [Cites] Cancer Treat Res. 2003;115:19-72 [12613192.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):495-505 [12620236.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):507-17 [12620237.001]
  • [Cites] Science. 2003 Apr 18;300(5618):445-52 [12702867.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):26120-6 [12714603.001]
  • [Cites] Arch Dermatol Res. 2003 Jul;295(3):93-101 [12768307.001]
  • [Cites] Curr Mol Med. 2003 Nov;3(7):643-51 [14601638.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13 [14967450.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2382-9 [15059889.001]
  • [Cites] Arch Dermatol. 2004 Jul;140(7):837-42 [15262694.001]
  • [Cites] J Clin Invest. 1999 Oct;104(7):855-64 [10510326.001]
  • [Cites] J Invest Dermatol. 1963 Jun;40:283-97 [14002987.001]
  • [Cites] Nat Med. 2005 Jan;11(1):20-1 [15635437.001]
  • [Cites] J Immunol. 2005 Apr 1;174(7):4271-8 [15778390.001]
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):329-41 [15970443.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] J Invest Dermatol. 2006 Apr;126(4):732-9 [16470170.001]
  • [Cites] J Invest Dermatol. 2006 Apr;126(4):869-81 [16470182.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):92-8 [17199573.001]
  • [Cites] Adv Cancer Res. 2000;77:25-79 [10549355.001]
  • [Cites] Adv Dermatol. 1999;14:261-83; discussion 284 [10643501.001]
  • [Cites] Mutat Res. 2000 May 30;450(1-2):193-9 [10838143.001]
  • [Cites] Hum Mutat. 2000;16(1):43-8 [10874304.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):3990-4003 [10921880.001]
  • [Cites] Cell. 2000 Jul 21;102(2):211-20 [10943841.001]
  • [Cites] Oncogene. 2000 Aug 31;19(37):4243-54 [10980598.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):32077-88 [10887174.001]
  • [Cites] Mol Biol Cell. 2004 Sep;15(9):4299-309 [15254267.001]
  • [Cites] J Invest Dermatol. 1984 Oct;83(4):296-301 [6207245.001]
  • [Cites] J Invest Dermatol. 1988 Jun;90(6):841-4 [2897396.001]
  • [Cites] Science. 1989 Feb 10;243(4892):811-4 [2916128.001]
  • [Cites] J Invest Dermatol. 1989 Jun;92(6):786-90 [2470827.001]
  • [Cites] Oncogene. 1990 Jul;5(7):953-62 [1973830.001]
  • [Cites] J Invest Dermatol. 1990 Aug;95(2):229-32 [2380581.001]
  • [Cites] Br J Dermatol. 1990 Jul;123(1):49-58 [2202427.001]
  • (PMID = 17525275.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / T32 AR007197; United States / NIAMS NIH HHS / AR / R21 AR 48405; United States / NIAMS NIH HHS / AR / T32 AR 07197
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AREG protein, human; 0 / Amphiregulin; 0 / BTC protein, human; 0 / Betacellulin; 0 / EGF Family of Proteins; 0 / EREG protein, human; 0 / Epiregulin; 0 / Glycoproteins; 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor alpha; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ PMC1899432
  •  go-up   go-down


2. Li X, Gast A, Rudnai P, Gurzau E, Koppova K, Hemminki K, Kumar R: ARLTS1 polymorphisms and basal cell carcinoma of the skin. Hered Cancer Clin Pract; 2007;5(1):25-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ARLTS1 polymorphisms and basal cell carcinoma of the skin.
  • Polymorphisms in the ARLTS1 gene, a member of the Ras super-family, have been associated with susceptibility in different cancer types.
  • The involvement of the gene in apoptotic signalling motivated us to study the role of ARLTS1 polymorphic variations in basal cell carcinoma of the skin (BCC).
  • In a case-control study, 529 cases diagnosed with BCC and 533 controls from Hungary, Romania and Slovakia were genotyped for the S99S (297G>A), P131L (392C>T), L132L (396G>C), C148R (442T>C) and W149X (446G>A) polymorphisms in the ARLTS1 gene.
  • No significant association between any of the single nucleotide polymorphisms (SNP) and risk of BCC (S99S, odds ratio (OR) 0.96, 95% confidence interval (CI) 0.601.53; P131L, OR 1.31 95%CI 0.742.31; L132L, OR 0.50, 95%CI 0.027.07; C148R, OR 0.50, 95%CI 0.691.18; and W149X, OR 1.01, 95%CI 0.372.79) was detected.
  • Furthermore, no significant difference in the distribution of haplotypes due to five polymorphisms in the ARLTS1 gene was found between the BCC cases and controls.
  • Our data rule out an association between variants in ARLTS1 and risk of BCC in the investigated population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Nov 15;131C(1):82-92 [15468170.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):468-73 [15761425.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10287-91 [17079447.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1573-6 [16581122.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):231-7 [15738985.001]
  • [Cites] Semin Cancer Biol. 2004 Feb;14(1):63-9 [14757536.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Arch Dermatol. 2001 Nov;137(11):1486-92 [11708952.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6640-8 [11559527.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2870-7 [11306461.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):172-5 [16488076.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1736-7 [16646072.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(1):59-62 [16570116.001]
  • [Cites] Carcinogenesis. 2006 Aug;27(8):1676-81 [16501254.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2505-8 [16353159.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1667-76 [15843669.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):850-60 [15516958.001]
  • (PMID = 19723348.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2736660
  •  go-up   go-down


3. Navarrete Isidoro O, Abad Fernández A, López Vime R, Jara Chinarro B, Juretschke Moragues MA: [Pulmonary metastasis of Basal cell carcinoma of the skin]. Arch Bronconeumol; 2005 Mar;41(3):169-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastasis of Basal cell carcinoma of the skin].
  • [Transliterated title] Metástasis pulmonares de un carcinoma basocelular cutáneo.
  • Basal cell carcinoma of the skin is a common neoplasm usually considered benign.
  • We report the case of a 41-year old man diagnosed with lung metastasis secondary to base cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Lung Neoplasms / secondary. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15766469.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Pezeshki A, Sari-Aslani F, Ghaderi A, Doroudchi M: p53 codon 72 polymorphism in basal cell carcinoma of the skin. Pathol Oncol Res; 2006;12(1):29-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 codon 72 polymorphism in basal cell carcinoma of the skin.
  • Basal cell carcinoma (BCC) is the most prevalent cancer in Iran.
  • In the present study the frequency of p53 codon 72 polymorphism in 91 patients with BCC of skin, compared to 465 healthy normal individuals, was investigated.
  • However, there was an apparent increase in the Arg/Arg genotype among those BCC patients who had a history of occupational sun exposure, compared to non-exposed patients (46.3% vs. 23.1%, P=0.11).
  • Our results suggest that Arg allele at codon 72 of p53 gene might affect the risk of ultraviolet-induced basal cell carcinoma.
  • [MeSH-major] Genes, p53 / genetics. Neoplasms, Basal Cell / genetics. Polymorphism, Genetic. Skin Neoplasms / genetics
  • [MeSH-minor] Codon. Environmental Exposure. Female. Genetic Predisposition to Disease. Humans. Iran. Male. Middle Aged. Occupational Exposure. Solar System. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2000 Apr;9(2):113-8 [10830578.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):684-90 [12628849.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2571-6 [12467072.001]
  • [Cites] Int J Cancer. 2000 Aug 15;87(4):528-33 [10918193.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Eur J Clin Invest. 2002 Dec;32(12):943-8 [12534455.001]
  • [Cites] Carcinogenesis. 1996 Feb;17(2):261-4 [8625447.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1385-7 [12820398.001]
  • [Cites] Int Arch Occup Environ Health. 2002 Apr;75(4):272-6 [11981662.001]
  • [Cites] Nat Genet. 2000 May;25(1):47-54 [10802655.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):2089-92 [14534749.001]
  • [Cites] Gene. 1988 Oct 30;70(2):245-52 [2905688.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4216-20 [8483937.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Jul 1;109(1):63-6 [12818446.001]
  • [Cites] J Biomed Sci. 2003 Jul-Aug;10(4):430-5 [12824702.001]
  • [Cites] J Dermatol Sci. 2002 May;29(1):1-9 [12007715.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):444-9 [12911720.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):199-205 [12706878.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 2002 Apr;33(2):274-5 [12575207.001]
  • [Cites] J Invest Dermatol. 2002 Jul;119(1):84-90 [12164929.001]
  • [Cites] Cancer Lett. 2002 May 28;179(2):175-83 [11888672.001]
  • [Cites] Arch Dermatol. 2000 Feb;136(2):245-6 [10677101.001]
  • [Cites] Nat Med. 1997 May;3(5):510-4 [9142118.001]
  • [Cites] Transplantation. 2000 Mar 15;69(5):994-6 [10755564.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):515-7 [11238194.001]
  • (PMID = 16554913.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Codon
  •  go-up   go-down


5. Rong Y, Welsh JS: Surface applicator calibration and commissioning of an electronic brachytherapy system for nonmelanoma skin cancer treatmenta). Med Phys; 2010 Oct;37(10):5509-5517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surface applicator calibration and commissioning of an electronic brachytherapy system for nonmelanoma skin cancer treatmenta).
  • PURPOSE: The Xoft Axxent<sup>®</sup> x-ray source has been used for treating nonmelanoma skin cancer since the surface applicators became clinically available in 2009.
  • The TG-61 in-air method was used as a guideline for acquiring nominal dose-rate output at the skin surface.
  • GafChromic<sup>®</sup> EBT films were used for testing the properties of the treatment fields with the skin applicators.
  • Patients with basal cell or squamous cell carcinoma were treated with eBx using a calibrated Xoft system with the low-energy x-ray source and the skin applicators.
  • RESULTS: The average nominal dose-rate output at the skin surface for the 35 mm applicator is 1.35 Gy/min with ±5% variation for 16 sources.
  • The output factor needs to be measured for each case with varying shapes of cutouts.
  • CONCLUSIONS: Together with TG-61, the authors' methodology provides comprehensive calibration procedures for medical physicists for using the Xoft eBx system and skin applicators for nonmelanoma skin cancer treatments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524537.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brachytherapy / Calibration / Cancer / Dosimetry / Dosimetry/exposure assessment / Ionization chambers / Lead / Radiation treatment / Skin / Standards and calibration / Surface treatments / Therapeutic applications, including brachytherapy / X-rays / basal cell carcinoma / biomedical equipment / brachytherapy / calibration / cancer / dosimetry / electronic brachytherapy / nonmelanoma skin cancer / skin / squamous cell carcinoma / surface applicator
  •  go-up   go-down


6. Dennler S, André J, Verrecchia F, Mauviel A: Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation. J Biol Chem; 2009 Nov 13;284(46):31523-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GLI2 (GLI-Kruppel family member 2), a zinc finger transcription factor that mediates Hedgehog signaling, is implicated in the progression of an ever-growing number of human malignancies, including prostate and pancreatic cancer, as well as basal cell carcinoma of the skin.
  • Its expression is up-regulated by transforming growth factor-beta (TGF-beta) in a variety of cell types, both normal and transformed.
  • This region harbors SMAD and lymphoid enhancer factor/T cell factor binding sites that allow functional cooperation between SMAD3 and beta-catenin, recruited to the promoter in response to TGF-beta to drive GLI2 gene transcription.
  • [MeSH-minor] Base Sequence. Blotting, Western. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cells, Cultured. Chromatin Immunoprecipitation. Cloning, Molecular. Humans. Keratinocytes / metabolism. Keratinocytes / pathology. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Luciferases / metabolism. Molecular Sequence Data. Protein Binding. RNA, Messenger / genetics. RNA, Messenger / metabolism. Regulatory Sequences, Nucleic Acid. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators / genetics. Trans-Activators / metabolism. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):781-5 [10693808.001]
  • [Cites] Hum Mol Genet. 2005 Aug 1;14(15):2181-8 [15994174.001]
  • [Cites] Curr Biol. 2001 May 15;11(10):769-73 [11378387.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5188-94 [12466281.001]
  • [Cites] Annu Rev Biochem. 2003;72:449-79 [12651739.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jul;36(7):1161-5 [15109563.001]
  • [Cites] Trends Biochem Sci. 2004 May;29(5):265-73 [15130563.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):42492-502 [15292219.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3091-100 [9606191.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1643-8 [10102636.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1923-6 [10489374.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1475-88 [15684397.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2783-810 [16322555.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(4):437-45 [16406505.001]
  • [Cites] Mol Cell Biol. 2006 May;26(9):3365-77 [16611981.001]
  • [Cites] Acta Oncol. 2006;45(4):375-88 [16760173.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):91-6 [16786128.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5924-8 [17062662.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):385-93 [17251379.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3583-93 [17440069.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6981-6 [17638910.001]
  • [Cites] Cell Cycle. 2007 Oct 15;6(20):2458-63 [17726373.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):50-6 [17721996.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10642-6 [18006803.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Dec;8(12):970-82 [18000526.001]
  • [Cites] Neoplasma. 2008;55(3):165-76 [18348648.001]
  • [Cites] Cancer Cell. 2008 May;13(5):394-406 [18455123.001]
  • [Cites] Cell Signal. 2008 Sep;20(9):1632-41 [18595660.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5769-77 [18794086.001]
  • [Cites] Genes Dev. 2008 Sep 15;22(18):2454-72 [18794343.001]
  • [Cites] J Biol Chem. 2008 Dec 19;283(51):35337-53 [18952601.001]
  • [Cites] Genes Dev. 2009 Jan 1;23(1):24-36 [19136624.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8358-63 [10890911.001]
  • (PMID = 19797115.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI2 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Smad3 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta; 0 / beta Catenin; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2797221
  •  go-up   go-down


7. Moloney FJ, Lyons JG, Bock VL, Huang XX, Bugeja MJ, Halliday GM: Hotspot mutation of Brahma in non-melanoma skin cancer. J Invest Dermatol; 2009 Apr;129(4):1012-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hotspot mutation of Brahma in non-melanoma skin cancer.
  • The Brahma (BRM) catalytic subunit of the SWI/SNF complex is one of two mutually exclusive subunits that provide energy for remodeling.
  • BRM has been identified as an important cancer susceptibility locus; however, to date no mutations have been identified in the BRM gene.
  • We performed genetic analysis of BRM in human non-melanoma skin cancers, precancerous lesions, and normal skin revealing a common nonsynonymous point mutation present in one of ten squamous cell and two of six basal cell carcinoma of the skin.
  • [MeSH-major] Point Mutation. Skin Neoplasms / genetics. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923443.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SMARCA2 protein, human; 0 / Transcription Factors
  •  go-up   go-down


8. Patel R, Adsay V, Andea A: Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma. Rare Tumors; 2010;2(1):e8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma.
  • Merkel cell carcinoma (MCC) or primary cutaneous neuroendocrine carcinoma is a malignant tumor considered to demonstrate differentiation towards Merkel cells that are present at the base of the epidermis or around the apical end of some hair follicles and are thought to play a yet uncertain role in sensory transduction.
  • Here we present the case of a 54- year old female with a basal cell carcinoma (BCC) of the skin with neuroendocrine features (positivity for chromogranin) that has evolved during multiple recurrences and radiotherapy into a high-grade neuroendocrine carcinoma with morphological and immunohistochemical features of MCC (trabecular and nesting arrangement, positivity for chromogranin, cytokeratin 20, neuron specific enolase, and also neurosecretory granules on electron microscopy).
  • The progression from a chromogranin positive basal cell carcinoma of the skin, to a high-grade neuroendocrine carcinoma demonstrates the potential for cross differentiation among skin tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139953.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994488
  • [Keywords] NOTNLM ; Merkel cell carcinoma / basal cell carcinoma / neuroendocrine
  •  go-up   go-down


9. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404670.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


10. Wilkening S, Hemminki K, Rudnai P, Gurzau E, Koppova K, Försti A, Kumar R: No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br J Dermatol; 2007 Aug;157(2):375-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
  • BACKGROUND: The MDM2 oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumour suppressor protein.
  • This SNP was also found to be associated with the onset and risk of different cancer types.
  • Basal cell carcinoma of the skin (BCC) is one of the most common neoplasms in the world.
  • BCC development is associated with environmental factors (especially sun exposure) as well as heritable factors.
  • OBJECTIVES: The present case-control study investigated the association of the MDM2 SNP309 with the risk and the age at onset of BCC.
  • Methods Data from 509 individuals affected by BCC and 513 healthy controls were genotyped with TaqMan polymerase chain reaction.
  • RESULTS: Cases and controls showed a similar genotype distribution and the SNP did not modify the age at onset of BCC.
  • CONCLUSIONS: These results suggest that the MDM2 SNP309 alone affects neither the risk nor the age at onset of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Polymorphism, Single Nucleotide. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Age of Onset. Aged. Aged, 80 and over. Case-Control Studies. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2008 Mar;158(3):636; author reply 636-7 [18076702.001]
  • (PMID = 17553029.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


11. Breuninger H, Sebastian G, Kortmann RD, Schwipper V, Werner J, Garbe C, Deutschen Krebsgesellschaft, Deutschen Dermatologischen Gesellschaft: [Brief guidelines: Basal cell carcinoma of the skin]. J Dtsch Dermatol Ges; 2006 May;4(5):441-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brief guidelines: Basal cell carcinoma of the skin].
  • [Transliterated title] Kurzleitlinie: Basalzellkarzinom der Haut.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Practice Guidelines as Topic. Practice Patterns, Physicians' / standards. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686614.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Germany
  •  go-up   go-down


12. Pandeya N, Purdie DM, Green A, Williams G: Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial. Am J Epidemiol; 2005 Apr 15;161(8):748-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial.
  • The aim of this study was to apply multifailure survival methods to analyze time to multiple occurrences of basal cell carcinoma (BCC).
  • Data from 4.5 years of follow-up in a randomized controlled trial, the Nambour Skin Cancer Prevention Trial (1992-1996), to evaluate skin cancer prevention were used to assess the influence of sunscreen application on the time to first BCC and the time to subsequent BCCs.
  • Sunscreen treatment was not associated with time to first occurrence of a BCC (hazard ratio = 1.04, 95% confidence interval: 0.79, 1.45).
  • Time to subsequent BCC tumors using the Andersen-Gill model resulted in a lower estimated hazard among the daily sunscreen application group, although statistical significance was not reached (hazard ratio = 0.82, 95% confidence interval: 0.59, 1.15).
  • Similarly, both the Wei-Lin-Weissfeld marginal-hazards and the Prentice-Williams-Peterson gap-time models revealed trends toward a lower risk of subsequent BCC tumors among the sunscreen intervention group.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / epidemiology. Sunscreening Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800267.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


13. McNaughton SA, Marks GC, Gaffney P, Williams G, Green AC: Antioxidants and basal cell carcinoma of the skin: a nested case-control study. Cancer Causes Control; 2005 Jun;16(5):609-18
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antioxidants and basal cell carcinoma of the skin: a nested case-control study.
  • OBJECTIVE: To investigate the relationship between basal cell carcinoma (BCC) and antioxidant nutrients, specifically carotenoids, vitamin E and selenium.
  • METHODS: The Nambour Skin Cancer Study is an ongoing, community-based study of randomly selected adult residents of a township in sub-tropical Queensland, Australia.
  • Using a nested case-control design, incident cases of BCC (n=90) were compared with age and sex matched controls (n=90).
  • Other determinants of skin cancer including sun exposure were also considered.
  • Dietary intakes were adjusted for energy intake, and serum carotenoids and vitamin E were adjusted for serum cholesterol.
  • RESULTS AND CONCLUSIONS: In this prospective study no significant associations were found between BCC and carotenoids, vitamin E or selenium, as measured by serum biomarkers or dietary intake, although there was a suggestion of a positive association with lutein intake.
  • [MeSH-major] Antioxidants / administration & dosage. Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Australia / epidemiology. Biomarkers / blood. Carotenoids / administration & dosage. Carotenoids / blood. Case-Control Studies. Diet Surveys. Dietary Supplements. Female. Humans. Logistic Models. Male. Middle Aged. Prospective Studies. Selenium / administration & dosage. Selenium / blood. Vitamin E / administration & dosage. Vitamin E / blood

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986117.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 1406-18-4 / Vitamin E; 36-88-4 / Carotenoids; H6241UJ22B / Selenium
  •  go-up   go-down


14. Campbell SM, Pye A, Horton S, Matthew J, Helliwell P, Curnow A: A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin. J Environ Pathol Toxicol Oncol; 2007;26(4):295-303
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin.
  • This investigation considered a novel method of enhancing penetration of the topical photosensitizing agent methyl aminolevulinate (MAL) into nodular basal cell carcinomas (BCCs) using an oxygen pressure injection device.
  • Oxygen pressure injection (OPI) is a method to drive compounds into skin using pressured oxygen.
  • The BCCs were then excised at different time intervals (0-180 min) and the depth of penetration of the MAL examined using microscopic fluorescence photometry to detect the production of the naturally fluorescent active photosensitiser protoporphyrin IX (PpIX).
  • Although it was difficult to compare quantitatively, as individual tumors in each of the different study groups varied, a definite trend of increase in relative tumor concentration of MAL-induced PpIX was observed over time, and this was enhanced when OPI was employed.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell. Drug Delivery Systems / methods. Photosensitizing Agents. Skin Neoplasms
  • [MeSH-minor] Humans. Injections, Intralesional. Microscopy, Fluorescence. Ointments. Photochemotherapy. Pilot Projects. Protoporphyrins / metabolism. Skin Absorption

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197827.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ointments; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


15. Ishida M, Kushima R, Okabe H: Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep; 2009 Oct;22(4):733-7
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin.
  • According to a previous study, beta III is not expressed in normal skin and squamous cell carcinoma.
  • However, its expression has not been examined in basal cell carcinoma (BCC) of the skin.
  • Expression of beta III was analyzed together with neural cell adhesion molecule (NCAM), chromogranin A, synaptophysin, epithelial membrane antigen (EMA) and cytokeratin (CK) 20 by immunohistochemical methods in 10 non-neoplastic skin tissues and 50 BCCs.
  • In the normal skin, immunoreactivity to beta III was restricted to the nerve bundles in the dermis and subcutis, no positivity was shown in epithelial cells of the epidermis and skin appendages. beta III and NCAM were expressed in 50 and 68% of BCCs, respectively, predominantly periphery of tumor nests, although the distribution of both markers was not always identical.
  • Chromogranin A, synaptophysin and CK 20 were not expressed in any of BCCs.
  • EMA was focally expressed in only 8% of BCCs. beta III is a potential candidate for inclusion to the panel of immunohistochemical markers to distinguish small BCCs from non-neoplastic hair buds, because non-neoplastic hair follicles are not positive for beta III.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Skin Neoplasms / metabolism. Tubulin / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromogranin A / biosynthesis. Female. Hair Follicle / metabolism. Humans. Immunohistochemistry. Keratin-20 / biosynthesis. Male. Middle Aged. Mucin-1 / biosynthesis. Neural Cell Adhesion Molecules / biosynthesis. Synaptophysin / biosynthesis. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724850.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Keratin-20; 0 / Mucin-1; 0 / Neural Cell Adhesion Molecules; 0 / Synaptophysin; 0 / TUBB3 protein, human; 0 / Tubulin
  •  go-up   go-down


16. Kang SY, Lee SJ, Hong SH, Chung YK, Oh HS, Kim SW, Yim DJ, Kim NK: Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase in squamous cell carcinoma and basal cell carcinoma of the skin. Mol Med Rep; 2010 Sep-Oct;3(5):741-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase in squamous cell carcinoma and basal cell carcinoma of the skin.
  • Genetic instability resulting from mutations in repair genes, defects in folic acid metabolism or DNA synthesis has been reported to contribute significantly to the development of skin cancer.
  • Thus, the present case-control study was conducted to determine whether an association exists between the MTHFR/TS polymorphisms and squamous cell carcinoma (SCC) and/or basal cell carcinoma (BCC) among Korean individuals.
  • The study subjects comprised 95 patients with SCC, 100 patients with BCC and 207 controls with no evidence of malignancy or pre-malignant lesions.
  • Patients with skin cancer and control samples were analyzed for polymorphisms of the MTHFR or TS genes by means of polymerase chain reaction-restriction fragment length polymorphism.
  • The MTHFR 677C>T and MTHFR 1298A>C polymorphisms showed no significance with regard to the development of SCC and BCC.
  • However, within the 6 bp insertion (ins)/deletion (del) polymorphism in the 3'-untranslated region (3'-UTR) of the TS gene, the BCC group showed statistical significance with a 2.8-fold increased risk of cancer development [adjusted odds ratio (AOR)=2.821] in heterozygous mutations (0 bp/6 bp), 7.5-fold (AOR=7.539) in homozygous mutations (6 bp/6 bp) and 3-fold (AOR=3.079) upon combination of heterozygous mutations and homozygous mutations (0 bp/6 bp + 6 bp/6 bp).
  • We thus conclude that the 6 bp ins/del polymorphism in the 3'-UTR is associated with increased risk of the development of skin cancer among Korean individuals with BCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21472308.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


17. Gorin MA, Iniesta MD, Douglas JA, Milliron KJ, Merajver SD: Absence of the CHEK2*1100delC mutation in non-BRCA1/2 families with multiple cancer types in a high-risk clinic population of Caucasian ancestry. J Clin Oncol; 2009 May 20;27(15_suppl):11040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of the CHEK2*1100delC mutation in non-BRCA1/2 families with multiple cancer types in a high-risk clinic population of Caucasian ancestry.
  • : 11040 Background: Checkpoint kinase 2(CHEK2) is a cell-cycle-checkpoint kinase that phosphorylates p53 and BRCA1 in response to DNA damage.
  • The contribution of CHEK2 mutations to familial cancer has been widely studied in breast cancer.
  • Most notably, the CHEK2*1100delC mutation has been characterized to confer a 2-fold increased risk for breast cancer in carriers.
  • This finding comes from studies performed on Northern and Eastern European populations.
  • In contrast to the work done in Europe, these studies suggest a lower frequency of CHEK2*1100delC mutations in breast cancer families.
  • The aim of this study was to determine the frequency of CHEK2*1100delC in members of breast cancer families who tested negative for a deleterious mutation in BRCA1/2.
  • Families were characterized by the presence of several cases of breast and/or ovarian cancer and multiple members with other cancers in a single lineage.
  • RESULTS: No CHEK2*1100delC mutations were detected in 115 individuals, including 39 women diagnosed with breast cancer at an early age, 7 women with bilateral cancer, 2 men with breast cancer and 6 women with ovarian cancer, all of whom were negative for mutations in BRCA1/2.The CHEK2 Breast Cancer Consortium previously reported a frequency of 2.3% for the CHEK2*1100delC mutation among breast cancer cases from families with at least 2 cases of breast cancer (or breast and ovarian cancer) in a first- or second-degree relationship.
  • CONCLUSIONS: Our data are consistent with previous reports that suggest a lower frequency of CHEK2*1100delC mutations in North American hereditary breast cancer families without BRCA1/2 mutations and enriched for multiple cancer types.
  • The low frequency of the CHEK2*1100delC in the North American population limits its clinical relevance as a cancer predisposing gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Olsson H, Attner B, Noreen D, Lithman T: Comorbidity prior to diagnosis in patients with common cancer diagnoses. J Clin Oncol; 2009 May 20;27(15_suppl):e22180

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity prior to diagnosis in patients with common cancer diagnoses.
  • : e22180 Background: Chronic disease as diabetes, hypertonia and anemia may be associated with cancer risk as well as affect the short term survival of the malignancy.
  • METHODS: Using population based registry data from specialist and primary care in our health care region comorbidity in the form of anemia, hypertonia, diabetes, rheumatoid arthritis, chronic obstructive pulmonary diasease (KOL), and alcohol related diseases for patients with colon-, rectal-, lung-, prostate and breast cancer and survival were studied.
  • Altogether 2047 colon cancer cases, 985 rectal cancer cases, 2017 lung cancer cases, 3578 breast cancer cases and 5106 prostate cancer cases diagnosed 2000-2005 were included.
  • Comorbidity was studied prior to cancer diagnosis and in order to compare with the general population all first comorbidity diagnoses within 90 days were censored.
  • Patients with colon and rectal cancer had a higher prevalence of anemia, and diabetes.
  • Patients with lung cancer had a higher prevalence of anemia, KOL, diabetes, rheumatoid arthritis for both men and women and for men also a higher prevalence of alcohol related diseases.
  • Except for alcohol related diseases in females with breast cancer comorbidity for the above diseases was not significantly elevated for breast or prostate cancer.
  • Survival of the different cancer diagnoses was not significantly related to the comorbidity except for a tendency of worse survival for patients with alcohol related disease.
  • CONCLUSIONS: The prevalence of some common chronic diseases are elevated especially in colon-, rectal and lung cancer patients.
  • The comorbidity does not seem to affect short term survival of the cancer patient except for alcohol related diagnoses.
  • Our study also indicates the necessity to have all levels of care included in the study base of comorbidity and also emphasizes the need to censor time prior to diagnosis when comparing data with the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963595.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Iturbe J Jr, Zwenger A, Lacava JA, Perez Verdera P, Vallejo C, Romero A, Leone JP, Perez J, Maccihavelli M, Leone B: Treatment of early breast cancer (EBC): A long-term follow-up study-GOCS experience. J Clin Oncol; 2009 May 20;27(15_suppl):e11610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of early breast cancer (EBC): A long-term follow-up study-GOCS experience.
  • : e11610 Background: Most cases of breast cancer are diagnosed at early stage of disease, therefore treatment is oriented to increase the relapse-free survival (RFS) and overall survival (OS).
  • RFS was analyzed from the date of initial diagnosis to the date of local or distant recurrence.
  • OS was estimated from the date of initial diagnosis to the last follow-up or date of death.
  • Adjuvant radiation therapy was administered to 73% of pts, whereas adjuvant chemotherapy to 29% and adjuvant hormone therapy to 18.5% of cases.
  • Local recurrence was documented in 37 pts (3.8%) whereas 269 developed metastatic disease (29%).
  • Bilateral breast cancer was seen in 102 cases (10.9%) and 91 pts (9.7%) developed 2nd malignancies.
  • This group of pts continues to have a good prognosis as shown by the OS rate at 5, 10, 15, 20 and 25 years, although high percentage of pts continue to have recurrence and die from breast cancer after 5, 10, 15, 20 and 25 years of follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961127.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR).
  • : 1519 Background: Skin cancers are the most common malignancies in OTR.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • Capecitabine, an orally-administered prodrug of 5-FU, in combination with interferon was shown to be effective in the treatment of advanced SCC of the skin.
  • This study was to determine the efficacy of low-dose capecitabine in secondary prevention of the skin cancers in OTR.
  • METHODS: OTR who developed recurrent skin cancers, SCC, and/or basal cell carcinoma (BCC), were given low-dose capecitabine 1g/m2 divided in two daily doses, day 1-14 of 21-day treatment cycle.
  • Skin surveillances were performed by dermatologists every 1 to 3 months.
  • Cumulative incidence rates of SCC, BCC, and AK before and after treatment were scored and statistically compared for each patient with a non-parametric Wilcoxon signed-rank test.
  • Mean incidence rates of SCC, BCC, and AK before treatment were 0.45, 0.05, and 4.99 lesions per month, respectively.
  • Mean incidence rates of SCC, BCC, and AK after treatment were 0.22, 0.04, and 2.80 lesions per month, respectively.
  • The differences in incidence rates of SCC, BCC, and AK before and after treatment were 0.24, 0.02, and 2.08 lesions per month with p value of 0.048, 0.844, and 0.151, respectively.
  • Age and the number of transplants were not significantly related to the change in incidence rates for all skin lesion types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Visram H, Dent SF: Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center. J Clin Oncol; 2009 May 20;27(15_suppl):e11613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center.
  • : e11613 Background: Male breast cancer (BC) comprises approximately 1% of all breast cancer cases, and over 80% of male BC tumours express the estrogen receptor (ER).
  • METHODS: We conducted a retrospective chart review of 24 pts diagnosed with male BC at the Ottawa Regional Cancer Centre from 1986-2003.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Booth CM, Li G, Mackillop WJ: The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: A population-based study in Ontario, Canada. J Clin Oncol; 2009 May 20;27(15_suppl):6505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: A population-based study in Ontario, Canada.
  • : 6505 Background: Lower SES is known to be associated with worsened cancer survival.
  • Here we evaluate the impact of SES on stage of cancer at diagnosis in Ontario which has universal health insurance.
  • METHODS: All incident cases of breast, colon, rectal, non-small cell lung, cervical and larynx cancer diagnosed in Ontario 2003-2005 were identified using the Ontario Cancer Registry.
  • Stage information is only captured routinely for patients seen at Ontario's 8 Regional Cancer Centers (RCCs).
  • Using a best stage grouping approach, cases were assigned stage based on pathologic TNM if available and clinical TNM otherwise.
  • Using postal code at time of diagnosis cases were assigned to quintiles (Q); Q1 represents the communities where the poorest 20% of the Ontario population resided.
  • RESULTS: Stage at diagnosis was available for 19,239/23,254 (83%) of cases seen at RCCs.
  • Among cases with breast cancer, those in Q1 were less likely to have stage I disease (43 vs 47%, p = 0.004) and more likely to have stage IV disease (5 vs 4%, 0.008) than Q2-5.
  • With lung cancer, cases in Q1 were more likely to have stage I disease compared to Q2-5 (16 vs 13%, p = 0.015).
  • Distribution of stage I and stage IV disease did not differ by SES across other individual diseases.
  • However, for all 6 cancers combined, cases in Q1 were less likely than Q2-5 to have stage I disease (27 vs 30%, p = 0.001) and more likely to have stage IV disease (21 vs 18%, p < 0.0001).
  • We found significant gradients in 3-year overall survival across Q1-Q5 for breast (5% absolute difference in survival, p < 0.001), colon (4%, p = 0.049), and cervical (18%, p = 0.031) cancers.
  • CONCLUSIONS: Despite universal health care, SES remains associated with survival among patients with cancer in Ontario.
  • These data suggest that the difference in outcome is only partially explained by differences in stage at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Maiti B, Kundranda MN, Jin T, Spiro TP, Daw HA: The association of metabolic syndrome with triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of metabolic syndrome with triple-negative breast cancer.
  • : 1038 Background: Metabolic syndrome, a conglomerate of obesity, insulin resistance, hypertriglyceridemia, low HDL (high density lipoprotein), and hypertension is associated with an increased risk of breast cancer.
  • However, no clear association has been shown between the highly aggressive triple-negative breast cancer and metabolic syndrome.
  • METHODS: In a retrospective review we compared triple-negative and non-triple-negative breast cancer cases for the presence of metabolic syndrome by NCEP (National Cholesterol Education Program) or AACE (American Association of Clinical Endocrinologists) definitions.
  • Data on metabolic syndrome criteria, tumor size, grade, lymph node status, and ductal carcinoma in situ (DCIS) were reviewed.
  • RESULTS: The entire cohort of 176 patients (12.5% African-American) with median age 56.5 years (range 26-91 years) comprised of 86 triple-negative cases and 90 non-triple-negative cases.
  • A statistically significant association of triple-negative breast cancer with metabolic syndrome was observed.
  • Contrary to blood glucose, triglyceride, or HDL levels, which independently showed significant association with triple-negative breast cancer, hypertension, or BMI showed no independent association.
  • Additionally, triple-negative tumors displayed a significantly higher histologic grade and relative paucity of ductal carcinoma in situ (DCIS) when compared to the non-triple negative tumors (p < 0.001).
  • CONCLUSIONS: The data suggests that the metabolic syndrome is significantly more prevalent in triple-negative breast cancer patients when compared to the non-triple-negative patients.
  • Additionally, triple-negative breast cancer showed a significantly higher histologic grade and a relative absence of DCIS.
  • Whether the presence of metabolic syndrome preferentially increases the risk of developing triple-negative-breast cancer needs to be elucidated by future prospective studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Shapiro G, Kwak E, Baselga J, Rodon J, Scheffold C, Laird AD, Bedell C, Edelman G: Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In preclinical cancer models XL147 is cytostatic or cytoreductive as monotherapy and enhances the efficacy of targeted agents and chemotherapeutics.
  • Drug-related toxicities included grade 3 skin rash (3 pts), grade 3 arterial thrombosis (1 pt), grade 2 transaminase elevation (1 pt), and grade 1 hyperglycemia (4 pts).
  • XL147 reached steady-state plasma concentrations by Day 15-20.
  • XL147 reduced levels of phosphorylated PI3K pathway components in PBMCs, hair, skin, and tumor tissues in an exposure-dependent manner.
  • As of December 2008, 6 pts (3 NSCLC, 1 BCC, 1 NHL, 1 PC) continued on study >6 months including 3 >10 months (NHL, NSCLC, BCC).
  • The most common drug-related toxicity was skin rash.
  • Prolonged stable disease has been observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961287.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Wilkening S, Hemminki K, Rudnai P, Gurzau E, Koppova K, Kumar R, Försti A: Case-control study in basal cell carcinoma of the skin: single nucleotide polymorphisms in three interleukin promoters pre-analysed in pooled DNA. Br J Dermatol; 2006 Dec;155(6):1139-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control study in basal cell carcinoma of the skin: single nucleotide polymorphisms in three interleukin promoters pre-analysed in pooled DNA.
  • BACKGROUND: Basal cell carcinoma (BCC) is one of the most common neoplasms in the world.
  • Development of BCC is associated with environmental factors (especially sun exposure) as well as heritable factors.
  • OBJECTIVES: To analyse three single nucleotide polymorphisms (SNPs) in the promoter regions of interleukin (IL) genes in genomic DNA from 527 cases of BCC and 530 matched controls and to examine if DNA pooling is a useful method on which to base decisions regarding further SNP analysis.
  • The DNA pools resulted from a division of the samples into cases and controls, female and male, and three age groups.
  • RESULTS: No significant association was found when the allele frequencies in cases and controls were compared.
  • However, by analysis of the individual genotypes we found SNP IL6-597 G/A to be significantly associated with BCC risk (P =0.007).
  • CONCLUSIONS: The association of SNP IL6-597 with BCC could be found only by individual genotyping, but would have been missed if only data from the pooling analysis had been known.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Polymorphism, Single Nucleotide. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Case-Control Studies. Female. Gene Frequency. Genotype. Humans. Interleukin-10 / genetics. Interleukin-1beta / genetics. Interleukin-6 / genetics. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107380.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


26. Bath-Hextall FJ, Perkins W, Bong J, Williams HC: Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev; 2007;(1):CD003412
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for basal cell carcinoma of the skin.
  • BACKGROUND: Basal cell carcinoma (BCC) is the commonest skin cancer.
  • BCCs are slow-growing, locally invasive, epidermal skin tumours which mainly affect white skinned people.
  • OBJECTIVES: To assess the effects of treatments for basal cell carcinoma.
  • SEARCH STRATEGY: We searched the Cochrane Skin Group Specialised Register (January 2006), the Cochrane Central Register of Controlled Trials (The Cochrane LIbrary Issue 1, 2006), the Cochrane Database of Systematic Reviews (The Cochrane Library Issue 1, 2006), MEDLINE (2004 to January 2006), EMBASE (2005 to January 2006), the metaRegister of Controlled Trials (February 2006).
  • SELECTION CRITERIA: Inclusion criteria were adults with one or more histologically proven, primary basal cell carcinoma.
  • One study found no significant difference for recurrence at 30 months when Moh's micrographic surgery was compared to surgery for high risk facial BCCs, (RR 0.64, 95%CI 0.16,2.64).
  • When radiotherapy was compared to cryotherapy there were significantly fewer recurrences at one year in the radiotherapy group compared to the cryotherapy group.Short-term studies suggest a success rate of 87 to 88% for imiquimod in the treatment of superficial BCC using a once-daily regimen for 6 weeks and a 76% treatment response when treating nodular BCC for 12 weeks, when measured histologically.
  • AUTHORS' CONCLUSIONS: Overall there has been very little good quality research on treatments for BCC.
  • Most trials have only evaluated BCCs in low risk locations.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateOf] Cochrane Database Syst Rev. 2003;(2):CD003412 [12804465.001]
  • (PMID = 17253489.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 63
  •  go-up   go-down


27. Kanitakis J, Chouvet B: Granular-cell basal cell carcinoma of the skin. Eur J Dermatol; 2005 Jul-Aug;15(4):301-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular-cell basal cell carcinoma of the skin.
  • Granular cell basal cell carcinoma (GBCC) is a very rare variant of BCC, of which ten cases have been reported in the literature.
  • We describe here a new case of GBCC studied immunohistochemically.
  • The tumor developed on the face of a 71-year old man and showed typical features of GBCC, i.e. a tumor reminiscent of nodular BCC consisting of cells with a granular eosinophilic cytoplasm.
  • [MeSH-major] Adenocarcinoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048765.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


28. Smeets N: Little evidence available on treatments for basal cell carcinoma of the skin. Cancer Treat Rev; 2005 Apr;31(2):143-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Little evidence available on treatments for basal cell carcinoma of the skin.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847982.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 12
  •  go-up   go-down


29. Pinto Pereira SM, Hipwell JH, McCormack VA, Tanner C, Moss SM, Wilkinson LS, Khoo LAL, Pagliari C, Skippage PL, Kliger CJ, Hawkes DJ, Dos Santos Silva IM: Automated registration of diagnostic to prediagnostic x-ray mammograms: Evaluation and comparison to radiologists' accuracy. Med Phys; 2010 Sep;37(9):4530-4539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: X-ray mammograms were simulated from MRIs of 20 women using finite element methods for modeling breast compressions and employing a MRI/x-ray appearance change model.
  • Five mammography film readers independently identified landmarks (tumor, nipple, and usually two other normal features) on pairs of diagnostic and corresponding prediagnostic digitized images from 52 breast cancer cases.
  • Registration accuracy was sensitive to the type of landmark and the amount of breast density.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524565.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Digital mammography / Film mammography / Finite element calculations / Image analysis / MRI / Magnetic resonance imaging / Mammography / Medical X-ray imaging / Medical imaging / Radiography / Registration / Tissues / X-ray imaging / affine transforms / biological organs / biomedical MRI / breast cancer / cancer / diagnostic radiography / finite element analysis / image registration / mammographic density / mammography / medical image processing / registration algorithms / tumours
  •  go-up   go-down


30. Wafa T: Contribution of BRCA1 and BRCA2 mutations to breast cancer in Tunisia. J Clin Oncol; 2009 May 20;27(15_suppl):e22191

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
  • : e22191 Background: Hereditary breast cancer accounts for 3-8% of all breast cancers.
  • It was recently estimated that a combination of BRCA1 and BRCA2 genes mutations is responsible for 30% of hereditary breast cancer cases.
  • METHODS: To investigate the prevalence of BRCA1 and BRCA2 gene mutations in breast cancer patients with affected relatives in Tunisia, 36 patients who had at least one first degree relative affected with breast and/or ovarian cancer were analysed.
  • Nineteen percent (7/36) of the familial cases were altered on BRCA1 or BRCA2 genes with deleterious mutations at heterozygous state and 55% (20/36) by mutation with uncertain value (UV) or by single nucleotide polymorphisms (SNPs).
  • CONCLUSIONS: Almost all the cases mutated by deleterious mutations on BRCA1 gene reported a family history of breast and/or ovarian cancer in the index case or in their relatives.
  • On the contrary, patients with an UV mutation or SNPs have no history of ovarian cancer in their corresponding families.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963625.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Wang X, Li Y, Cao X: False-positive diagnosis of breast cancer by diffused optical tomography with ultrasound. J Clin Oncol; 2009 May 20;27(15_suppl):e22085

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-positive diagnosis of breast cancer by diffused optical tomography with ultrasound.
  • : e22085 Background: Breast cancer is one of the most common cancer in women.
  • Early detection, early diagnosis and early treatment play key role in fighting against breast cancer.
  • It provides dual modality images for early diagnosis of breast cancer.
  • The aim of this study was to evaluate the OPTIMUS system on diagnosis of breast disease.
  • METHODS: OPTIMUS system was applied to 160 breast tumor patients.
  • All patients had received surgical treatment and had definite pathological diagnosis.
  • OPTIMUS system was evaluated as diagnostic tool of breast tumor in this study.
  • RESULTS: There were 42 cases diagnosed as benign breast disease and 118 cases diagnosed as breast cancer by OPTIMUS system.
  • Pathology confirmed 60 cases of benign disease and 100 cases of breast cancer.
  • False positive rate of breast cancer was 30% (18/60).
  • False negative rate of breast cancer was 0% (0/100).
  • The pathology of false positive cases was mild and severe papillomatosis (6/18), non-typical hyperplasia (4/18), chronic inflammation (3/18), fibroadenoma (3/18) and fat necrosis (2/18).
  • Papillomatosis and non-typical hyperplasia are precancerous lesions and often difficult for clinical diagnosis.
  • CONCLUSIONS: OPTIMUS system is a non- invasive and highly effective diagnostic tool for breast disease.
  • Its sensitivity is reached to 100% and specificity is about 70% on the diagnosis of breast cancer.
  • OPTIMUS system could be used as assistant diagnostic tool for breast tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963263.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Hao X, Liu Y, Hui R, Zhang J: Comparison of the sensitivity to endocrine therapy of PR+/ER- patients and ER+/PR- patients with HER2+ breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the sensitivity to endocrine therapy of PR+/ER- patients and ER+/PR- patients with HER2+ breast cancer.
  • : e11558 Background: Her2 and PR expression are important indicators for prognosis of breast cancer.
  • METHODS: Collected 3,677 primary breast cancer cases from 2002 to 2004 in Tianjin University Cancer Hospital.
  • All of the cases were confirmed by pathohistological method.
  • With Her2+ breast cancer, 168 patients are PR+/ER- and 211 patients are ER+/PR-.
  • With Her2+ BC, 3-year DFS(disease-free survival rate) of PR+/ER- patients is 94.53%, higher than that of PR-/ER+ ones (91.81%).With Her2- BC, 3-year DFS of PR+/ER- patients is lower than that of PR-/ER+ (p<0.05).
  • 3. Total of 1853 cases with 5-year followed up, and 1297 cases have been given endocrine therapy.
  • CONCLUSIONS: With Her2+ breast cancer, 3-year DFS of PR+/ER- patients is higher than ER+/PR- and also PR+/ER- patients may more sensitive to endocrine therapy than ER+/PR- patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964105.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Gombos EC, Esserman LE, Poppiti RJ Jr: Basal cell carcinoma of the skin presenting as microcalcifications on screening mammography. Breast J; 2005 Mar-Apr;11(2):149
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the skin presenting as microcalcifications on screening mammography.
  • [MeSH-major] Breast Neoplasms. Calcinosis. Carcinoma, Basal Cell. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730466.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Gercovich N, Gil Deza E, Russo M, Garcia Gerardi C, Diaz C, Morgenfeld E, Rolnik B, Emina J, Rivarola E, Gercovich FG: Early-stage male breast cancer: A 10-year experience. J Clin Oncol; 2009 May 20;27(15_suppl):e11630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage male breast cancer: A 10-year experience.
  • : e11630 Introduction: Male breast cancer is very rare, representing only between 0.7% and 1% of all breast cancers, and only half of them are early stage cases.
  • OBJECTIVE: The present study has been designed with the aim of studying retrospectively the clinical onset and evolution of male invasive breast cancer patients (stages I and II) treated at IOHM between 1997 and 2008.
  • METHODS: The records of 3,000 breast cancer cases followed between 1997 and 2008 were searched, looking for male stage I and II breast cancer patients.
  • Tumoral type= Invasive Ductal Carcinoma 12 pt.
  • Tumoral subtype= NOS 9 pt (75%) Apocrine 2 pt (17%) Micropapillar 1 pt (8%).
  • Twelve stage I and II male breast cancer patients were identified out of 3000 (0.4%) breast cancer cases diagnosed and followed in the past 10 years at the IOHM.
  • 2. Mastectomy was the surgical procedure in 11 of the 12 cases 3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961181.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Karagas MR, Nelson HH, Zens MS, Linet M, Stukel TA, Spencer S, Applebaum KM, Mott L, Mabuchi K: Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology; 2007 Nov;18(6):776-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure.
  • BACKGROUND: Epidemiologic studies consistently find enhanced risk of basal cell carcinoma of the skin among individuals exposed to ionizing radiation, but it is unclear whether the radiation effect occurs for squamous cell carcinoma.
  • METHODS: We analyzed data from a case-control study of keratinocyte cancers in New Hampshire.
  • Incident cases diagnosed in 1993-1995 and 1997-2000 were identified through a state-wide skin cancer surveillance system, and controls were identified through the Department of Transportation and Center for Medicare and Medicaid Service Files (n = 1121 basal cell carcinoma cases, 854 squamous cell carcinoma cases, and 1049 controls).
  • RESULTS: We found an association between history of radiation treatment and basal cell carcinoma.
  • The association was especially strong for basal cell carcinomas arising within the radiation treatment field (odds ratio = 2.6; 95% confidence interval = 1.5-4.3), and among those treated with radiation therapy before age 20 (3.4; 1.8-6.4), those whose basal cell carcinomas occurred 40 or more years after radiation treatment (3.2; 1.8-5.8), and those treated with radiation for acne (11; 2.7-49).
  • Similar age and time patterns of risk were observed for squamous cell carcinoma, although generally with smaller odds ratios.
  • For basal cell carcinoma, early exposure to radiation treatment was a risk factor largely among those without a history of severe sunburns, whereas for squamous cell carcinoma, radiation treatment was a risk factor primarily among those with a sun-sensitive skin type (ie, a tendency to sunburn).
  • CONCLUSIONS: Radiation treatment, particularly if experienced before age 20, seems to increase the long-term risk of both basal and squamous cell carcinomas of the skin.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917604.001).
  • [ISSN] 1044-3983
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082354; United States / NCI NIH HHS / CA / CA23108; United States / NCI NIH HHS / CA / CA57494; United States / NCI NIH HHS / CA / CA58290
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


37. Kozyreva ON, Konnikov N: The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e14646

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy.
  • : e14646 Background: Non-melanoma skin cancer (NMSC) is the most common form of human cancer.
  • RESULTS: 43 Caucasian males (range 59- 87 yrs), 37 (87%) had history of NMSC on the face or scalp, 32 (78%) had basal cell carcinoma (BCC), 11 (22%) squamous cell carcinoma (SCC), 100% of patients had multiple (>4) AKs prior to treatment and 23 (75% ) had moderate to severe DH determined by Griffiths scale.
  • Prior to ALA-PDT 74 NMSC's were documented: 40 (54%) BCC and 34 (46%) SCC.
  • 46 NMSC's were documented following ALA-PDT: 22 (48%) BCC and 24 (52%) SCC.
  • Prior to ALA-PDT, the frequency of BCC averaged 2 [IQR 1 to 3, max=4], and the frequency of SCC averaged 1 [IQR 1 to 1, max=3].
  • Following ALA-PDT, the occurrence of BCC averaged 1 [IQR 0 to 1, max=5], and that of SCC averaged 1 [IQR 0 to 2, max= 4].
  • The difference between BCC frequency before and after ALA-PDT treatment shown a significant reduction in BCC incidence (P = 0.0018).
  • No such differences were observed between the frequency of SCC before and after ALA-PDT (P=0.6230) Conclusions: A single ALA-PDT treatment to the face or scalp in high risk patients significantly reduces the incidence of BCC, the incidence of SCC was not reduced.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Cheretis C, Dietrich F, Chatzistamou I, Politi K, Angelidou E, Kiaris H, Mkrtchian S, Koutselini H: Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma. Am J Dermatopathol; 2006 Oct;28(5):410-2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma.
  • To test if ERp29 is associated with the pathogenesis of skin cancer, in the present study we have assessed the expression of ERp29 in basal-cell carcinoma of the skin.
  • A bank of 104 basal skin carcinoma, including 50 nodular, 29 infiltrating, 15 superficial, 7 sclerosing, 2 fibroepithelial, and 1 pigmented cell carcinoma, were assessed by immunohistochemistry for ERp29 expression.
  • Thirty-nine (37.5%) of the samples tested expressed ERp29 with the infiltrating carcinomas displaying more intense (++,+++) immunoreactivity (6/29, P < 0.05) and the superficial carcinomas exhibiting the less intense anti-ERp29 staining (1/15, P < 0.05).
  • Collectively our results suggest that ERp29 is expressed in a subset of basal-cell carcinoma of the skin with the infiltrating carcinomas exhibiting the highest incidence of immunopositivity.
  • The role of ERp29 in the pathogenesis of the disease and its potential diagnostic value should be explored in future investigations.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Endoplasmic Reticulum / secretion. Heat-Shock Proteins / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17012915.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ERP29 protein, human; 0 / Heat-Shock Proteins
  •  go-up   go-down


39. Paavilainen V, Tuominen J, Aho VV, Saari KM: Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland. Eur J Ophthalmol; 2007 Jul-Aug;17:494-500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland.
  • : . PURPOSE: Basal cell carcinoma (BCC) is the most common skin cancer of the eyelid, showing an increasing incidence in the white population.
  • The authors studied the clinical characteristics and the treatment results of BCC of the eyelid in southwestern Finland during 1977-1997.
  • METHODS: The authors reviewed the case records of 191 patients with BCC of the eyelids treated at the Turku University Eye Clinic during 1977-1997.
  • RESULTS: The 191 patients had altogether 194 BCC tumors of the eyelid with the mean diameter of the tumor being smaller than 10 mm in 77.3% of cases.
  • Of the 194 BCC tumors of the eyelid 16.0% showed recurrence, and the recurrence rate of all surgically treated tumors was 13.7%.
  • In this study 61 patients (31.9%) developed other malignancies than the BCC of the eyelid including 28 patients (14.7 %) with carcinoma in other locations than skin.
  • CONCLUSIONS: Incompletely removed BCCs of the eyelid showed only 18.9% recurrence rate during the follow-up time.
  • On the other hand, BCCs of the eyelid should not be underestimated because of the rather high total recurrence rate.
  • The frequency of 31.9% of other malignancies than BCC of the eyelid is remarkably high and requires special attention from the ophthalmologist taking care of the patient with BCC of the eyelid.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221540.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


40. Blázquez-Sánchez N, de Troya-Martín M, Frieyro-Elicegui M, Fúnez-Liébana R, Martín-Márquez L, Rivas-Ruiz F: Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma. Actas Dermosifiliogr; 2010 Sep;101(7):622-628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma.
  • [Transliterated title] Análisis de costes de la cirugía micrográfica de Mohs en el carcinoma basocelular facial de alto riesgo.
  • INTRODUCTION: Mohs micrographic surgery (MMS) is the treatment of choice for high-risk facial basal cell carcinoma (BCC) as it offers the greatest chance of cure with maximum preservation of healthy tissue.
  • OBJECTIVES: To determine the cost of MMS with fresh tissue to treat high-risk facial BCC and compare this to the estimated cost of conventional surgery in a Spanish public hospital.
  • MATERIAL AND METHODS: Cross-sectional study of a consecutive series of patients with high-risk facial BCC who underwent MMS at the Department of Dermatology at Hospital Costa del Sol in Malaga, Spain between July 2006 and December 2007.
  • RESULTS: Seventy-nine patients (mean age, 62 years) with 81 high-risk facial BCCs, 97.5% of which were primary tumors, underwent MMS.
  • Histology showed that 64% of the tumors were infiltrative or micronodular carcinomas.
  • Tumor-free margins were achieved in all patients, with no more than 2 stages required in 88% of the cases.
  • The most common surgical reconstruction techniques were direct closure (21%) and closure with a local skin flap or graft (71%); the corresponding estimates for conventional surgery were 2% and 89%, respectively.
  • CONCLUSIONS: MMS is a viable, effective technique that does not generate significantly higher costs than conventional surgery in selected patients with high-risk facial BCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y AEDV. All rights reserved.
  • (PMID = 28709544.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliograficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Análisis de costes / Cirugía micrográfica / Cost analysis / Cost-effectiveness / Coste/beneficio / Micrographic surgery / Mohs
  •  go-up   go-down


41. Wuest M, Dummer R, Urosevic M: Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod. Arch Dermatol Res; 2007 Dec;299(10):493-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod.
  • Basal cell carcinoma of the skin (BCC) is the most common skin tumor in Caucasians worldwide.
  • Different therapeutic options are available to treat BCC, including topical immunotherapy.
  • Imiquimod is topical Toll-like receptor 7 agonist that activates anti-tumor immune response and has been recently approved for the treatment of superficial BCC (sBCC).
  • We sought to investigate the influence of imiquimod treatment on the members of the Notch signaling pathway, whose activity is known to be decreased in BCCs.
  • [MeSH-major] Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma, Basal Cell / drug therapy. Signal Transduction / drug effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922128.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Calcium-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 0 / delta protein; 134324-36-0 / Serrate proteins; 99011-02-6 / imiquimod
  •  go-up   go-down


42. Brellier F, Bergoglio V, Valin A, Barnay S, Chevallier-Lagente O, Vielh P, Spatz A, Gorry P, Avril MF, Magnaldo T: Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures. Oncogene; 2008 Nov 20;27(51):6601-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures.
  • Basal cell carcinoma of the skin is the most common type of cancer in humans.
  • In this study, we took advantage of the natural genotype (PATCHED(+/-)) of healthy keratinocytes expanded from patients with the nevoid basal cell carcinoma or Gorlin syndrome to mimic heterozygous somatic mutations thought to occur in the PATCHED gene early upon basal cell carcinoma development in the general population.
  • Deciphering the phenotype of PATCHED(+/-) keratinocytes revealed slight increases of the transcriptional activators GLI1 and GLI2-the latter known to provoke basal cell carcinoma-like tumors when overexpressed in transgenic mice.
  • PATCHED(+/-) keratinocytes also showed a substantial increase of the cell cycle regulator cyclin D1.
  • These data show for the first time the physiological impact of constitutive heterozygous PATCHED mutations in primary human keratinocytes and strongly argue for a yet elusive mechanism of haploinsufficiency leading to cancer proneness.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Mutation. Receptors, Cell Surface / genetics. Skin / pathology. Skin Neoplasms / genetics
  • [MeSH-minor] Base Sequence. Cell Transformation, Neoplastic / genetics. Cells, Cultured. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor / physiology. Genetic Predisposition to Disease. Heterozygote. Humans. Keratinocytes / metabolism. Keratinocytes / pathology. Male. Middle Aged. Models, Biological. Organ Culture Techniques


43. Sneddon JB: The contribution of niche-derived factors to the regulation of cancer cells. Methods Mol Biol; 2009;568:217-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contribution of niche-derived factors to the regulation of cancer cells.
  • In normal adult tissues, paracrine signals that derive from the stem cell niche, or microenvironment, play an important role in regulating the critical balance between activity and quiescence of stem cells.
  • Similarly, evidence has emerged to support the hypothesis that signals derived from the microenvironment regulate cancer cells in an analogous manner.
  • We recently reported that in basal cell carcinoma of the skin and in diverse other solid tumors, fibroblasts that comprise the tumor cell niche are, indeed, molecularly distinct from those that comprise the normal stroma.
  • [MeSH-major] Biological Factors / metabolism. Cell Culture Techniques / methods. Neoplastic Stem Cells / pathology. Stem Cell Niche / pathology
  • [MeSH-minor] Cell Separation. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Fibroblasts / cytology. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. RNA / genetics. RNA / metabolism. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582430.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biological Factors; 0 / GREM1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 63231-63-0 / RNA
  •  go-up   go-down


44. Chuprov IN: [Basal-cell carcinoma of the skin]. Arkh Patol; 2007 Nov-Dec;69(6):52-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal-cell carcinoma of the skin].
  • The paper represents an overview of updated literature concerning common skin neoplasms.
  • The clinical manifestation of the basal cell carcinoma varies significantly according to the patients age, tumor size, localization and duration of the neoplastic process, histological type of the tumor, including proliferative activity and stromal reactions.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290385.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


45. Thievessen I, Wolter M, Prior A, Seifert HH, Schulz WA: Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines. J Cell Physiol; 2005 May;203(2):372-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines.
  • Constitutive activation of hedgehog signaling, often caused by PTCH1 inactivation and leading to inappropriate activation of GLI target genes, is crucial for the development of several human tumors including basal cell carcinoma of the skin and medulloblastoma.
  • The PTCH1 gene at 9q22 is also considered as a candidate tumor suppressor in transitional cell carcinoma (TCC), of which >50% show LOH in this region.
  • We have therefore investigated GLI-dependent promoter activity and expression of hedgehog pathway components in TCC cell lines and proliferating normal urothelial cells.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Cell Transformation, Neoplastic / metabolism. Gene Expression Regulation, Neoplastic / physiology. Signal Transduction / physiology. Trans-Activators / metabolism. Urinary Bladder Neoplasms / metabolism. Urothelium / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Genes, Tumor Suppressor. Hedgehog Proteins. Humans. Membrane Proteins / genetics. Membrane Proteins / metabolism. Promoter Regions, Genetic / genetics. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism. Veratrum Alkaloids / pharmacology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15521068.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Veratrum Alkaloids; 0 / patched receptors; ZH658AJ192 / cyclopamine
  •  go-up   go-down


46. Laner-Plamberger S, Kaser A, Paulischta M, Hauser-Kronberger C, Eichberger T, Frischauf AM: Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes. Oncogene; 2009 Apr 2;28(13):1639-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sustained Hedgehog (HH) signaling is implicated in basal cell carcinoma of the skin and other types of cancer.
  • Here we show that GLI1 and GLI2, the main transcriptional activators of the HH pathway, directly regulate expression of the activator protein 1 (AP-1) family member JUN, a transcription factor controlling keratinocyte proliferation and skin homeostasis.
  • Some of these cooperatively activated genes are involved in cell-cycle progression, which is consistent with a significant reduction of the proliferative potential of GLI in the absence of JUN.
  • These results suggest a novel connection between HH/GLI pathway activity and JUN, which may contribute to the oncogenic activity of HH/GLI signaling in skin.
  • [MeSH-minor] Base Sequence. Binding Sites. Cell Proliferation. Cells, Cultured. Hedgehog Proteins / genetics. Hedgehog Proteins / physiology. Humans. Keratinocytes / metabolism. Keratinocytes / physiology. Phosphorylation. Promoter Regions, Genetic. Protein Binding / physiology. Protein Kinases / metabolism. Signal Transduction / genetics. Up-Regulation / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19219074.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Proto-Oncogene Proteins c-jun; 0 / Transcription Factors; EC 2.7.- / Protein Kinases
  •  go-up   go-down


47. Galloway TJ, Morris CG, Mancuso AA, Amdur RJ, Mendenhall WM: Impact of radiographic findings on prognosis for skin carcinoma with clinical perineural invasion. Cancer; 2005 Mar 15;103(6):1254-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of radiographic findings on prognosis for skin carcinoma with clinical perineural invasion.
  • BACKGROUND: The objective of the current study was to correlate pretreatment computed tomography and magnetic resonance imaging studies with outcomes for patients with squamous or basal cell carcinoma of the skin and clinical perineural invasion.
  • Patients were stratified as follows: imaging negative, 10 patients; minimal or moderate peripheral disease, 14 patients; and central and/or macroscopic disease, 21 patients.
  • RESULTS: The 5-year local control rates were as follows: imaging negative, 76%; minimal or moderate peripheral disease, 57%; and central and/or macroscopic disease, 25%.
  • The 5-year absolute and cause-specific survival rates were as follows: imaging negative, 90% and 100%, respectively; minimal or moderate peripheral disease, 50% and 56%, respectively; and central and/or macroscopic disease, 58% and 61%, respectively.
  • Patients who had imaging-positive minimal or moderate peripheral disease had a better local control rate but a similar survival rate compared with patients who had central and/or macroscopic disease.
  • [MeSH-major] Carcinoma, Basal Cell / radiography. Carcinoma, Squamous Cell / radiography. Neoplasm Invasiveness / pathology. Skin Neoplasms / radiography
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Sampling Studies. Sensitivity and Specificity. Sex Factors. Survival Analysis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693020.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Wilkening S, Hemminki K, Thirumaran RK, Bermejo JL, Bonn S, Försti A, Kumar R: Determination of allele frequency in pooled DNA: comparison of three PCR-based methods. Biotechniques; 2005 Dec;39(6):853-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pools were made of genomic DNA samples from 96 cases with basal cell carcinoma of the skin and 96 healthy controls with known genotypes.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382903.001).
  • [ISSN] 0736-6205
  • [Journal-full-title] BioTechniques
  • [ISO-abbreviation] BioTechniques
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Galvan A, Noci S, Mancuso M, Pazzaglia S, Saran A, Dragani TA: Genetic background modulates gene expression profile induced by skin irradiation in ptch1 mice. Int J Radiat Oncol Biol Phys; 2008 Dec 1;72(5):1582-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic background modulates gene expression profile induced by skin irradiation in ptch1 mice.
  • PURPOSE: Ptch1 germ-line mutations in mice predispose to radiation-induced basal cell carcinoma of the skin, with tumor incidence modulated by the genetic background.
  • Here, we examined the possible mechanisms underlying skin response to radiation in F1 progeny of Ptch1(neo67/+) mice crossed with either skin tumor-susceptible (Car-S) or -resistant (Car-R) mice and X-irradiated (3 Gy) at 2 days of age or left untreated.
  • METHODS AND MATERIALS: We conducted a gene expression profile analysis in mRNA samples extracted from the skin of irradiated or control mice, using Affymetrix whole mouse genome expression array.
  • RESULTS: Analysis of the gene expression profile of normal skin of F1 mice at 4 weeks of age revealed a similar basal profile in the nonirradiated mice, but alterations in levels of 71 transcripts in irradiated Ptch1(neo67/+) mice of the Car-R cross and modulation of only eight genes in irradiated Ptch1(neo67/+) mice of the Car-S cross.
  • CONCLUSIONS: These results indicate that neonatal irradiation causes a persistent change in the gene expression profile of the skin.
  • The tendency of mice genetically resistant to skin tumorigenesis to show a more complex pattern of transcriptional response to radiation than do genetically susceptible mice suggests a role for this response in genetic resistance to basal cell tumorigenesis.
  • [MeSH-major] Gene Expression Profiling / methods. Germ-Line Mutation. Receptors, Cell Surface / genetics. Skin / radiation effects
  • [MeSH-minor] Animals. Carcinoma, Basal Cell / genetics. Crosses, Genetic. Genetic Predisposition to Disease. Genome. Mice. Mice, Knockout. Mice, Mutant Strains. RNA, Messenger / genetics. RNA, Messenger / radiation effects. Reverse Transcriptase Polymerase Chain Reaction. Skin Neoplasms / genetics. Transcription, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028281.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


50. Scherer D, Bermejo JL, Rudnai P, Gurzau E, Koppova K, Hemminki K, Kumar R: MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. Int J Cancer; 2008 Apr 15;122(8):1787-93
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism.
  • The variants within the human melanocortin 1 receptor (MC1R) gene are associated with an increased risk of different skin cancers.
  • In this study, we genotyped by direct sequencing, 529 cases of basal cell carcinoma of the skin (BCC) and 533 healthy controls for polymorphisms in the entire MC1R gene.
  • The risk of BCC in the carriers of MC1R variants with fair complexion was almost twice as much as in the corresponding noncarriers.
  • The carriers of the R163Q variant with a medium skin complexion were at a 3-fold higher risk than the noncarrier counterparts.
  • The interaction, of effect on the BCC risk, between the MC1R variants and types of skin response to sun exposure was greater than multiplicative.
  • Our data confirmed the status of the nonsynonymous MC1R variants as independent genetic risk factors for BCC.
  • However, the mechanism through which the variants influence the risk likely involves complex interactions with other genetic and host risk factors.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Receptor, Melanocortin, Type 1 / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Arginine. Case-Control Studies. Female. Genetic Predisposition to Disease. Genotype. Glutamine. Humans. Hungary. Male. Methionine. Middle Aged. Risk Factors. Romania. Sequence Analysis, DNA. Slovakia. Threonine

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067130.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Receptor, Melanocortin, Type 1; 0 / X-ray repair cross complementing protein 3; 0RH81L854J / Glutamine; 2ZD004190S / Threonine; 94ZLA3W45F / Arginine; AE28F7PNPL / Methionine
  •  go-up   go-down


51. Taskinen M, Ranki A, Pukkala E, Jeskanen L, Kaitila I, Mäkitie O: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. Am J Med Genet A; 2008 Sep 15;146A(18):2370-5
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.
  • Cartilage-hair hypoplasia (CHH) is an autosomal recessive chondrodysplasia with short stature, sparse hair and defective cell-mediated immunity.
  • It is caused by mutations in the RMRP (ribonuclease mitochondrial RNA processing) gene, encoding the RNA component of the ribonuclease complex RNase MRP.
  • The aim of this study was to further elucidate the risk and spectrum of cancer in CHH.
  • A cohort of 123 Finnish patients with CHH (51 males) was followed for malignancy through the Finnish Cancer Registry.
  • The number of identified cancers was compared with expected numbers of cancer using population-based data to obtain standardized incidence ratios (SIR).
  • During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12).
  • Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180) followed by squamous cell carcinoma (3), leukemia (1) and Hodgkin lymphoma (1).
  • In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61).
  • Patients with CHH have significantly increased risk for developing non-Hodgkin lymphoma or basal cell carcinoma at early age; the overall prognosis is poor.
  • Careful follow-up, extending beyond pediatric age, is warranted for early diagnosis of malignancies.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Osteochondrodysplasias / epidemiology. Registries. Skin Neoplasms / epidemiology


52. Kochneva EV, Filonenko EV, Vakulovskaya EG, Scherbakova EG, Seliverstov OV, Markichev NA, Reshetnickov AV: Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials. Photodiagnosis Photodyn Ther; 2010 Dec;7(4):258-67
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials.
  • Protocols were designed for PDT of basal cell carcinoma of the skin to result in GCP (Good Clinical Practice)-conformed randomized phase II clinical studies.
  • There was no normal skin/subdermal tissue damage after both laser and sun light exposure.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Chlorophyll / analogs & derivatives. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 21112549.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / bremachlorin; 1406-65-1 / Chlorophyll
  •  go-up   go-down


53. Koljonen V, Kukko H, Tukiainen E, Böhling T, Sankila R, Joensuu H, Pukkala E: Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study. Cancer Epidemiol; 2010 Feb;34(1):62-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study.
  • Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma of the skin.
  • MCCs and some other skin cancers, such as basal cell carcinomas, frequently harbour Merkel cell polyomavirus DNA.
  • The purpose of the study was to investigate the frequency of second cancers following the diagnosis of MCC.
  • We studied the incidence of second primary cancers after the diagnosis of MCC from the files of the Finnish Cancer Registry in 1979-2006.
  • Among the 172 MCC patients identified a total of 34 second primary cancers were detected in 30 individuals after the diagnosis of MCC.
  • The MCC patients had an increased risk for a subsequent cancer (any site) compared to age-, gender- and calendar period-matched general population (standardized incidence ratio [SIR] 2.34; 95% confidence interval [CI], 1.62-3.27).
  • The risks for basal cell carcinoma of the skin (O=11), SIR, 3.48; 95% CI, 1.74-6.22 and chronic lymphocytic leukemia (O=2), SIR, 17.9; 95% CI, 2.16-64.6 were significantly elevated.
  • The SIRs for an overall second primary cancer risk did not change markedly with time since the diagnosis of MCC.
  • We conclude that patients diagnosed with MCC have an increased risk for a second cancer.
  • This risk may in part result from shared etiological factors between MCC and other tumour types, such as immunosuppression or possibly Merkel cell polyomavirus infection.
  • [MeSH-major] Carcinoma, Merkel Cell / epidemiology. Neoplasms, Second Primary / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / epidemiology. Cohort Studies. Female. Finland / epidemiology. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061203.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


54. Boran C, Parlak AH, Erkol H: Collision tumour of trichofolliculoma and basal cell carcinoma. Australas J Dermatol; 2007 May;48(2):127-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumour of trichofolliculoma and basal cell carcinoma.
  • Histopathological examination revealed that the nodule was composed of trichofolliculoma and basal cell carcinoma.
  • The diagnosis was made as a collision tumour of trichofolliculoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Hair Follicle / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Trichofolliculoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535204.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


55. Corrêa Mde P, Ferreira AP, Gollner AM, Rodrigues MF, Guerra MC: [Markers expression of cell proliferation and apoptosis in basal cell carcinoma]. An Bras Dermatol; 2009 Nov-Dec;84(6):606-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Markers expression of cell proliferation and apoptosis in basal cell carcinoma].
  • [Transliterated title] Expressão de marcadores de proliferação celular e apoptose em carcinoma basocelular.
  • BACKGROUND: - Basal cell carcinoma is the most common form of human cancer.
  • OBJECTIVE - To correlate markers expression of apoptosis (p53 and bcl-2) and cell proliferation (Ki-67 and PCNA) with histological indicators of tumor severity.
  • METHODS - Five samples of the nodular, morpheaform and superficial types of carcinoma were studied, respectively.One control group with three lesion-free patients was also included in the study.
  • The Mann-Whitney test was used to compare these markers expression with the manifestation form of basal cell carcinoma.
  • RESULTS - Bcl-2 expression was significant in basal cell carcinomas said to be aggressive (morpheaform and nodular types).
  • Of the studied tumors, 66.7% (n =10) strongly expressed p53.Our results show a greater expression of Ki-67 in nodular and superficial basal cell carcinoma, with no expression in the controls.
  • CONCLUSION - The findings allow us to conclude that Bcl-2 and p53 show a tendency to indicate the severity of basal cell carcinoma.
  • Also, PCNA was not a good marker of cell proliferation.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Cell Proliferation. Skin Neoplasms / chemistry. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191172.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC: Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol; 2005 Jun;152(6):1108-24
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular aetiology and pathogenesis of basal cell carcinoma.
  • Recent insights into the cell biology of the epidermis and its appendages are transforming our understanding of the pathogenesis of basal cell carcinoma (BCC).
  • The significant progress that has been made warrants a comprehensive review of the molecular and cellular pathology of BCC.
  • The items addressed include environmental and genetic risk factors, the biology of the putative precursor cell(s), and the contribution of aberrations in processes such as apoptosis, cell proliferation, differentiation and signalling to carcinogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Apoptosis. Cell Differentiation. Cell Proliferation. Epidermis / metabolism. Epidermis / pathology. Genetic Predisposition to Disease. Humans. Immunosuppression. Immunotherapy. Risk Factors. Ultraviolet Rays / adverse effects. Virus Diseases / complications. Virus Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2006 Apr;154(4):790-1 [16536838.001]
  • (PMID = 15948971.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 308
  •  go-up   go-down


57. Krahl D, Sellheyer K: Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol; 2007 Oct;34(10):782-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma.
  • It is diagnostically highly reliable in the differentiation between basal cell carcinoma and cutaneous squamous cell carcinoma.
  • In this study, we report its application in the differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and basal cell carcinoma.
  • METHODS: Biopsy samples from 28 sclerosing and infiltrating basal cell carcinomas, 13 microcystic adnexal carcinomas and 16 desmoplastic trichoepitheliomas were examined after immunohistochemical staining with Ber-EP4.
  • RESULTS: Ber-EP4 did not label any of the microcystic adnexal carcinomas, whereas all 28 basal cell carcinomas were Ber-EP4 positive.
  • Only one basal cell carcinoma was weakly positive.
  • Twelve of the 16 desmoplastic trichoepitheliomas were immunoreactive with Ber-EP4 and the staining was more variable than those of basal cell carcinomas.
  • CONCLUSIONS: Ber-EP4 reliably differentiates microcystic adnexal carcinoma from basal cell carcinoma to the same extent as it distinguishes the latter tumor from squamous cell carcinoma.
  • While it stains the majority of desmoplastic trichoepitheliomas, these tumors still have to be considered in the differential diagnosis with microcystic adnexal carcinoma, when Ber-EP4 is applied.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / diagnosis. Carcinoma, Skin Appendage / diagnosis. Skin / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Fluorescent Antibody Technique, Indirect. Humans. Sclerosis / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880584.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


58. Lee S, Cnaan RB, Paramanathan N, Davies M, Benger R, Ghabrial R: Subconjunctival "ring" recurrence of Basal cell carcinoma of the globe. Ophthal Plast Reconstr Surg; 2010 Mar-Apr;26(2):117-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subconjunctival "ring" recurrence of Basal cell carcinoma of the globe.
  • Basal cell carcinoma is the most common indication for orbital exenteration.
  • The recurrence rate of BCC removed with microscopically controlled histology sections is up to 6%.
  • The authors describe the recurrence of a lower eyelid BCC resected with microscopic control that did not manifest itself until 15 years later as a subconjunctival lesion, encircling the globe, and without apparent skin involvement.
  • BCC can present in any manner following surgery, and therefore, judicious follow-up is necessary even after microscopically controlled resection.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305512.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Gambichler T, Orlikov A, Vasa R, Moussa G, Hoffmann K, Stücker M, Altmeyer P, Bechara FG: In vivo optical coherence tomography of basal cell carcinoma. J Dermatol Sci; 2007 Mar;45(3):167-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo optical coherence tomography of basal cell carcinoma.
  • BACKGROUND: Optical coherence tomography (OCT) is a promising non-invasive imaging technique that has not systematically been studied in skin cancer such as basal cell carcinoma (BCC).
  • OBJECTIVE: We aimed, first, to describe the in vivo histologic features of BCC by using OCT, and second, to find out whether it is possible to differentiate BCC subtypes by means of OCT.
  • METHODS: Prior to the excision, the BCCs (n=43) as well as adjacent non-lesional skin sites were assessed by OCT in vivo.
  • RESULTS: Compared to non-lesional skin, a loss of normal skin architecture and disarrangement of the epidermis and upper dermis was observed in the OCT images of BCCs.
  • With regard to the aforementioned OCT features, no statistically significant (P<0.05) difference was found between nodular, multifocal superficial, and infiltrative BCCs, respectively.
  • CONCLUSIONS: OCT is capable to visualize altered skin architecture and histopathological correlates of BCC.
  • However, there is not at this time sufficient data supporting the clinical use of OCT for the differentiation of BCC subtypes.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Tomography, Optical Coherence
  • [MeSH-minor] Aged. Dermis / pathology. Diagnosis, Differential. Epidermis / pathology. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17215110.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


60. Uhara H, Hayashi K, Koga H, Saida T: Multiple hypersonographic spots in basal cell carcinoma. Dermatol Surg; 2007 Oct;33(10):1215-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple hypersonographic spots in basal cell carcinoma.
  • BACKGROUND: High-frequency ultrasound is a useful method to obtain preoperative information regarding extension of basal cell carcinoma.
  • Its contribution to diagnosis is generally limited, however.
  • Recently, we observed hypersonographic spots in some cases of basal cell carcinoma.
  • OBJECTIVE: The present study was performed to determine the diagnostic value of this finding in this type of tumor.
  • MATERIALS AND METHODS: We conducted a retrospective study of archived sonographic images with a 30- or 15-MHz scanner and histology specimens of a total of 85 lesions, consisting of 29 basal cell carcinomas and 56 melanomas.
  • RESULTS: The findings were classified into four patterns as follows: Type A, multiple (more than five spots/lesion) hypersonographic spots (14 cases, 48%); Type B, sparse (3-5 spots/lesion) hypersonographic spots (7 cases, 24%); Type C, multiple moderate sonographic spots (3 cases, 10%); and Type D, sparse moderate sonographic spots (5 cases, 17%).
  • Histopathologically, these hypersonographic spots in BCCs seemed to correspond to calcification, horn cysts, or clusters of apoptotic cells in the centers of nests of basal cell carcinoma.
  • CONCLUSION: Multiple hypersonographic spots might become a useful finding for differential diagnosis between basal cell carcinoma and melanoma.
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Melanoma / ultrasonography. Skin Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Basal Cell Carcinoma, Multiple.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903154.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. de Zwaan SE, Haass NK: Genetics of basal cell carcinoma. Australas J Dermatol; 2010 May;51(2):81-92; quiz 93-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of basal cell carcinoma.
  • Basal cell carcinoma is the most common human malignancy in populations of European origin, and Australia has the highest incidence of basal cell carcinoma in the world.
  • Great advances in the understanding of the genetics of this cancer have occurred in recent years.
  • Mutations of the patched 1 gene (PTCH1) lead to basal cell carcinoma predisposition in Gorlin syndrome.
  • PTCH1 is part of the hedgehog signalling pathway, and derangements within this pathway are now known to be important in the carcinogenesis of many different cancers including sporadic basal cell carcinoma.
  • The molecular biology of the hedgehog pathway is discussed, and mouse models of basal cell carcinoma based on this pathway are explored.
  • New developments in non-surgical treatment of basal cell carcinoma are based on this knowledge.
  • Other genes of importance to basal cell carcinoma development include the tumour suppressor gene P53 and the melanocortin-1 receptor gene.
  • Evidence of familial aggregation of this cancer is explored and supports the possibility of genetic predisposition to this common malignancy.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / therapy. Disease Models, Animal. Genetic Predisposition to Disease. Hedgehog Proteins / genetics. Humans. Mice. Mutation. Receptor, Melanocortin, Type 1 / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546211.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Receptor, Melanocortin, Type 1; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Protein p53; 0 / patched receptors
  •  go-up   go-down


62. Thirumaran RK, Bermejo JL, Rudnai P, Gurzau E, Koppova K, Goessler W, Vahter M, Leonardi GS, Clemens F, Fletcher T, Hemminki K, Kumar R: Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin. Carcinogenesis; 2006 Aug;27(8):1676-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin.
  • In addition to environmental exposures like UV radiation and, in some cases, arsenic contamination of drinking water, genetic factors may also influence the individual susceptibility to basal cell carcinoma of skin (BCC).
  • In the present study, 529 cases diagnosed with BCC and 533 controls from Hungary, Romania and Slovakia were genotyped for one polymorphism in each of seven DNA repair genes.
  • The variant allele for T241M (C>T) polymorphism in the XRCC3 gene was associated with a decreased cancer risk [odds ratio (OR), 0.73; 95% confidence interval (CI), 0.61-0.88; P = 0.0007, multiple testing corrected P = 0.004].
  • The risk of multiple BCC was significantly lower among variant allele carriers than in non-carriers (P = 0.04).
  • Men homozygous for the C-allele for E185Q (G>C) polymorphism in the NBS1 gene showed an increased BCC risk (OR, 2.19; 95% CI, 1.23-3.91), but not women (OR, 0.84; 95% CI, 0.49-1.47).
  • The data from this study show overall risk modulation of BCC by variant allele for T241M polymorphism in XRCC3 and gender-specific effect by E185Q polymorphism in NBS1.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. DNA Repair. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cell Cycle Proteins / genetics. Child. Child, Preschool. Female. Genetic Predisposition to Disease. Genotype. Humans. Hungary / epidemiology. Male. Middle Aged. Nuclear Proteins / genetics. Odds Ratio. Risk Factors. Romania / epidemiology. Slovakia / epidemiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501254.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / NBN protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


63. Vogler N, Meyer T, Akimov D, Latka I, Krafft C, Bendsoe N, Svanberg K, Dietzek B, Popp J: Multimodal imaging to study the morphochemistry of basal cell carcinoma. J Biophotonics; 2010 Oct;3(10-11):728-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal imaging to study the morphochemistry of basal cell carcinoma.
  • Basal cell carcinoma is the most abundant malignant neoplasm in humans, the pathology of which is characterized by an abnormal proliferation of basal cells.
  • Basal cell carcinoma can show a variety of different morphologies, which are based on different cellular biology.
  • Furthermore, the carcinoma often grows invisibly to the eye imbedded in the surrounding skin.
  • Therefore, in some cases its clinical detection is challenging.
  • Thus, our work aims at establishing an unsupervised tissue classification method based on multimodal imaging and the application of chemometrics to discriminate basal cell carcinoma from non-diseased tissue.
  • A case study applying multimodal imaging to ex-vivo sections of basal cell carcinoma is presented.
  • In doing so, we apply a combination of various linear and non-linear imaging modalities, i.e. fluorescence, Raman and second-harmonic generation microscopy, to study the morphochemistry of basal cell carcinoma.
  • The joint information content obtained by such multimodal approach in studying various aspects of the malignant tissue alterations associated with basal cell carcinoma is discussed.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Molecular Imaging / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20648521.001).
  • [ISSN] 1864-0648
  • [Journal-full-title] Journal of biophotonics
  • [ISO-abbreviation] J Biophotonics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Paavilainen V, Tuominen J, Pukkala E, Saari KM: Basal cell carcinoma of the eyelid in Finland during 1953-97. Acta Ophthalmol Scand; 2005 Apr;83(2):215-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelid in Finland during 1953-97.
  • PURPOSE: To study the incidence of basal cell carcinoma (BCC) of the eyelid in Finland.
  • METHODS: We studied 6241 cases of BCC of the eyelid reported to the nationwide Finnish Cancer Registry during 1953-97.
  • RESULTS: The incidence rates of BCC of the eyelid varied between 0.7 and 3.0 per 100 000 person-years in men and between 0.5 and 2.8 per 100 000 person-years in women during the study period.
  • The age-adjusted incidence rates of BCC of the eyelid increased during 1953-87 (p < 0.0001).
  • The incidence of BCC of the eyelid rose significantly with age.
  • There were no significant differences in standardized incidence ratios (SIRs) for BCC of the eyelid between different social class and occupation categories.
  • CONCLUSION: Age-adjusted incidence rates showed that BCC of the eyelid was more than twice as frequent during 1978-97 than before 1968.
  • Ageing may partly explain the increased incidence of BCC of the eyelid, whereas there were no differences in the SIRs for BCC of the eyelid between different social class and occupation categories in Finland.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Eyelid Neoplasms / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15799736.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


65. Potier A, Avenel Audran M, Belperron P, Briand E, Croue A, Verret JL: [Basal cell carcinoma of the first toenail]. Ann Dermatol Venereol; 2007 Oct;134(10 Pt 1):757-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell carcinoma of the first toenail].
  • [Transliterated title] Carcinome basocellulaire de l'appareil unguéal de l'hallux.
  • BACKGROUND: Basal cell carcinoma is a very common form of skin cancer but its occurrence on the toenail unit is very rare.
  • We report such a case of basal cell carcinoma localized on the proximal nail fold of the right hallux.
  • CASE REPORT: A 67-year-old woman had a 7-year history of a non-healing ulcer on the proximal nail fold of the right hallux after antibiotics and treatment of her onychomycosis.
  • Bowen's disease and squamous cell carcinoma were suspected.
  • Histopathologic examination of a biopsy specimen revealed infiltrative basal cell carcinoma.
  • The lesion was surgically excised with a 0.5 cm margin and the defect was repaired by full-thickness skin graft with good functional and cosmetic results.
  • DISCUSSION: Basal cell carcinoma is the most common skin cancer but its localization on fingers, toes and nail units is very rare.
  • Only six cases of basal cell carcinoma on the toe nail unit have been reported to date in the literature.
  • Our case emphasizes the value of biopsy for all nail unit lesions of atypical appearance, course or therapeutic response.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nail Diseases / pathology. Nails. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978714.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


66. Cicchi R, Massi D, Sestini S, Carli P, De Giorgi V, Lotti T, Pavone FS: Multidimensional non-linear laser imaging of Basal Cell Carcinoma. Opt Express; 2007 Aug 6;15(16):10135-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidimensional non-linear laser imaging of Basal Cell Carcinoma.
  • We have used a multidimensional non-linear laser imaging approach to visualize ex-vivo samples of basal cell carcinoma (BCC).
  • A combination of several non-linear laser imaging techniques involving fluorescence lifetime, multispectral two-photon and second-harmonic generation imaging has been used to image different skin layers.
  • This approach has elucidated some morphological (supported by histopathological images), biochemical, and physiochemical differences of the healthy samples with respect to BCC ones.
  • In particular, in comparison with normal skin, BCC showed a blue-shifted fluorescence emission, a higher fluorescence response at 800 nm excitation wavelength and a slightly longer mean fluorescence lifetime.
  • The results obtained provide further support for in-vivo non-invasive imaging of Basal Cell Carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547362.001).
  • [ISSN] 1094-4087
  • [Journal-full-title] Optics express
  • [ISO-abbreviation] Opt Express
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Gulia A, Altamura D, De Trane S, Micantonio T, Fargnoli MC, Peris K: Pigmented reticular structures in basal cell carcinoma and collision tumours. Br J Dermatol; 2010 Feb 1;162(2):442-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented reticular structures in basal cell carcinoma and collision tumours.
  • BACKGROUND: The dermatoscopic diagnosis of basal cell carcinoma (BCC) is based on well-known specific criteria.
  • Despite the fact that a pigment network is considered a negative feature for the diagnosis of BCC, its detection in a BCC context has been reported in 2.8% of cases.
  • OBJECTIVES: To determine whether pigment networks or network-like structures might represent a pitfall for the correct diagnosis of BCC.
  • METHODS: Dermatoscopic images of 412 histopathologically proven BCCs were analysed retrospectively.
  • RESULTS: Pigment network or network-like structures were detected in 14 of 412 (3.4%) BCCs.
  • Nine of 14 BCCs presented a typical pigment network, due to the association of a BCC lesion with a naevus, solar lentigo or actinic keratosis; two BCCs located on the face showed a pseudonetwork, and three of 14 lesions displayed a network-like structure characterized by light-brown irregularly meshed short linear structures, histopathologically related to a hyperpigmentation of the basal layer of the epidermis.
  • CONCLUSIONS: The presence of a pigment network in the context of a BCC is uncommon, and it usually reflects the association of BCC with a solar lentigo, naevus or a specific location of the lesion on photodamaged skin.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Dermoscopy / methods. Melanins. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Retrospective Studies. Skin Pigmentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754866.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


68. Kleydman Y, Manolidis S, Ratner D: Basal cell carcinoma with intracranial invasion. J Am Acad Dermatol; 2009 Jun;60(6):1045-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with intracranial invasion.
  • The risk of invasion and destruction of cranium, underlying dura, and cranial nerves by basal cell carcinoma (BCC) is extremely low, with an estimated incidence of 0.03%.
  • Intracranial BCC invasion by direct extension is rare, and orbital spread from a nasal lesion has not been reported in the literature.
  • We describe a case of intracranial invasion of a multiply recurrent nasal BCC, which caused progressive bilateral blindness from optic nerve compression, with spinal canal involvement causing subsequent lower extremity weakness and paralysis.
  • This case underscores the importance of early and appropriate treatment of high risk BCC, and aggressive treatment of recurrent lesions as early as possible.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Orbit / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Blindness / etiology. Female. Humans. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467376.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Rodriguez C, Barriuso V, Chan LS: Extensive basal cell carcinoma with probable bone metastasis. Cutis; 2007 Jul;80(1):60-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive basal cell carcinoma with probable bone metastasis.
  • Metastasis of basal cell carcinoma (BCC) rarely occurs.
  • Few cases have been reported in the literature; those cases reported generally resulted from chronic, extensive, recurrent lesions on the head or neck.
  • With regard to bone metastases, several case reports have demonstrated similar clinical features indicative of osseous involvement.
  • We present a case report of a patient with an extensive BCC with histologic documentation and probable bone metastasis of BCC.
  • Clinical and radiographic features of this case were consistent with previously reported patients.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725067.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


70. Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, Sotiropoulou PA, Blanpain C: Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol; 2010 Mar;12(3):299-305
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the cell lineage at the origin of basal cell carcinoma.
  • For most types of cancers, the cell at the origin of tumour initiation is still unknown.
  • Here, we used mouse genetics to identify cells at the origin of basal cell carcinoma (BCC), which is one of the most frequently occurring types of cancer in humans, and can result from the activation of the Hedgehog signalling pathway.
  • Using mice conditionally expressing constitutively active Smoothened mutant (SmoM2), we activated Hedgehog signalling in different cellular compartments of the skin epidermis and determined in which compartments Hedgehog activation induces BCC formation.
  • Activation of SmoM2 in hair follicle bulge stem cells and their transient amplifying progenies did not induce cancer formation, demonstrating that BCC does not originate from bulge stem cells, as previously thought.
  • Using clonal analysis, we found that BCC arises from long-term resident progenitor cells of the interfollicular epidermis and the upper infundibulum.
  • Our studies uncover the cells at the origin of BCC in mice and demonstrate that expression of differentiation markers in tumour cells is not necessarily predictive of the cancer initiating cells.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Cell Lineage. Epidermis / pathology
  • [MeSH-minor] Animals. Bacterial Proteins / genetics. Bacterial Proteins / metabolism. Cadherins / metabolism. Cell Count. Cell Differentiation. Clone Cells / metabolism. Clone Cells / pathology. Ear, External / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Genes, Reporter / genetics. Hair Follicle / metabolism. Hair Follicle / pathology. Hedgehog Proteins / genetics. Integrases / genetics. Integrin beta4 / metabolism. Keratin-10 / metabolism. Keratin-14 / genetics. Keratin-15 / genetics. Keratin-15 / metabolism. Keratin-19 / genetics. Kruppel-Like Transcription Factors / metabolism. Luminescent Proteins / genetics. Luminescent Proteins / metabolism. Mice. Mice, Inbred Strains. Mice, Transgenic. Models, Biological. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Proteins / genetics. Proteins / metabolism. RNA, Untranslated. Receptors, Cell Surface / metabolism. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Skin / metabolism. Skin / pathology. Tail / pathology

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cell Stem Cell. 2010 Apr 2;6(4):292-4 [20362530.001]
  • (PMID = 20154679.001).
  • [ISSN] 1476-4679
  • [Journal-full-title] Nature cell biology
  • [ISO-abbreviation] Nat. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cadherins; 0 / Gt(ROSA)26Sor non-coding RNA, mouse; 0 / Hedgehog Proteins; 0 / Integrin beta4; 0 / Keratin-14; 0 / Keratin-15; 0 / Keratin-19; 0 / Krt1-10 protein, mouse; 0 / Krt1-14 protein, mouse; 0 / Krt1-15 protein, mouse; 0 / Kruppel-Like Transcription Factors; 0 / Luminescent Proteins; 0 / Proteins; 0 / RNA, Untranslated; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Shh protein, mouse; 0 / Smo protein, mouse; 0 / patched receptors; 0 / yellow fluorescent protein, Bacteria; 147785-83-9 / Keratin-10; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


71. Griffin JR, Cohen PR, Tschen JA, Mullans EA, Schulze KE, Martinelli PT, Nelson BR: Basal cell carcinoma in childhood: case report and literature review. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S97-102
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in childhood: case report and literature review.
  • Childhood onset basal cell carcinoma is uncommon.
  • In addition to occurring in children with albinism, Bazex syndrome, basal cell carcinoma nevus syndrome, nevus sebaceus, radiotherapy-treated cancers, solid organ transplants, and xeroderma pigmentosum, childhood onset basal cell carcinoma has also occurred, albeit less commonly, de novo.
  • We describe a boy with idiopathic childhood onset basal cell carcinoma.
  • Previously published children with de novo basal cell carcinoma were collected from computerized medical literature search (PubMed) and citations from earlier reports.
  • To our knowledge, childhood onset idiopathic basal cell carcinoma has been observed in a total of 107 children, including our patient.
  • Basal cell carcinoma in children may be associated with prior sun exposure.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938034.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


72. Telfer NR, Colver GB, Morton CA, British Association of Dermatologists: Guidelines for the management of basal cell carcinoma. Br J Dermatol; 2008 Jul;159(1):35-48
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the management of basal cell carcinoma.
  • This article represents a planned regular updating of the previous British Association of Dermatologists guidelines for the management of basal cell carcinoma.
  • These guidelines present evidence-based guidance for treatment, with identification of the strength of evidence available at the time of preparation of the guidelines, and a brief overview of epidemiological aspects, diagnosis and investigation.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18593385.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Review
  • [Publication-country] England
  • [Number-of-references] 181
  •  go-up   go-down


73. Alcalay J, Ben-Amitai D, Alkalay R: Idiopathic basal cell carcinoma in children. J Drugs Dermatol; 2008 May;7(5):479-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiopathic basal cell carcinoma in children.
  • Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in humans, and is the most common malignant neoplasm among adults in the US.
  • Childhood onset of BCC is rare and usually associated with genetic disorders such as basal cell nevus syndrome, Bazex syndrome, albinism, and xeroderma pigmentosum or due to radiation therapy.
  • A girl with idiopathic onset of BCC who was treated with Mohs micrographic surgery is reported.
  • A total of 108 children including this patient were reported with idiopathic de novo BCC.
  • Basal cell carcinoma in children is probably the result of genetic background and intense ultraviolet radiation exposure.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505143.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Weyers W, Hörster S, Diaz-Cascajo C: Tumor of follicular infundibulum is Basal cell carcinoma. Am J Dermatopathol; 2009 Oct;31(7):634-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor of follicular infundibulum is Basal cell carcinoma.
  • Tumor of follicular infundibulum (TFI) is currently thought to be a benign epithelial neoplasm with follicular differentiation.
  • It is encountered commonly in association with basal cell carcinoma (BCC), often as an incidental finding.
  • We reexamined 24 cases of TFI and noted, often only focally, many changes typical of BCC, including palisading of cells at the periphery of aggregations, germinative cells, follicular germs in the absence of a follicular papilla, crowding of cells, individual necrotic neoplastic cells, fibromucinous stroma, and clefts between aggregations of neoplastic cells and stroma.
  • Five cases were associated with BCC, and 2 of them showed obvious continuity between both types of lesions.
  • Moreover, we observed recurrences of what seemed to be a completely removed BCC in which tiny columns of cells typical of TFI were present in surgical margins.
  • Those findings prompted us to conclude that TFI may be one of many manifestations of BCC rather than a differential diagnosis of it.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652582.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Gerritsen MJ, De Rie MA, Beljaards RC, Thissen MR, Kuipers MV: Survey among patients with basal cell carcinoma in The Netherlands. J Dermatolog Treat; 2009;20(4):213-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survey among patients with basal cell carcinoma in The Netherlands.
  • This paper describes the findings of a survey distributed among Dutch patients with basal cell carcinoma (BCC).
  • The questionnaire comprised a list of questions related to demographic characteristics, features of BCC, reason for consulting a dermatologist, anxiety, type of treatment and the satisfaction with this treatment and desired benefits of treatment.
  • Half of the patient group had already previously experienced a BCC.
  • Most patients (52%) indicated that the diagnosis 'skin cancer' frightened them, but that they knew it could be treated.
  • Accordingly, most patients (70%) indicated that BCC had no or hardly any influence on their quality of life.
  • From the patient's perspective, efficacy, low recurrence rate and no or minor scarring are important features of a BCC treatment.
  • The number of BCC patients is growing, which will lead to a definite burden for dermatologists in the near future.
  • [MeSH-major] Carcinoma, Basal Cell. Patient Satisfaction / statistics & numerical data. Skin Neoplasms. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125362.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Pham TT, Selim MA, Burchette JL Jr, Madden J, Turner J, Herman C: CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol; 2006 Feb;33(2):123-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in trichoepithelioma and basal cell carcinoma.
  • BACKGROUND: Trichoepithelioma (TE) is a benign neoplasm that shares both clinical and histologic features with basal cell carcinoma (BCC).
  • METHODS: CD10 protein immunohistochemistry was performed on paraffin-embedded biopsies of 13 TE and 23 BCC diagnosed by routine microscopy.
  • Cases were analyzed for pattern of CD10 expression by tumor cells and surrounding stroma.
  • Of these, eight cases also demonstrated positivity of the papilla, and two also showed positivity of the basaloid cells.
  • On the other hand, expression of CD10 by basaloid cells was identified in 20 (87%) cases of BCC.
  • Stromal positivity was also identified in three cases of BCC.
  • Condensation of CD10-positive stromal cells around basaloid nests was statistically significant in differentiating TE from BCC (p < 0.0001).
  • Conversely, CD10-positive basaloid cells were seen predominantly in BCC (p < 0.0001).
  • CONCLUSIONS: This study demonstrates a statistically significant difference in CD10 staining pattern between TE and BCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Neoplasms, Basal Cell / metabolism. Neprilysin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Immunohistochemistry. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420307.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


77. Mostafa WZ, Mahfouz SM, Bosseila M, Sobhi RM, El-Nabarawy E: An immunohistochemical study of laminin in basal cell carcinoma. J Cutan Pathol; 2010 Jan;37(1):68-74
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of laminin in basal cell carcinoma.
  • BACKGROUND: Laminins are components of the extracellular matrix that mediate cell adhesion, growth, migration, proliferation and differentiation.
  • Basement membrane (BM) laminins, in particular, may play a role in enhancing carcinoma cell motility.
  • AIM: To evaluate the distribution pattern of laminin in basal cell carcinoma (BCC), as regards the basement membrane, cellular cytoplasm, peritumoral lacunae and surface epithelium and to correlate laminin distribution with different variants of BCC.
  • PATIENTS AND METHODS: Skin biopsy specimens were obtained from 21 BCC patients for routine histopathological and immunohistochemical study.
  • Code No: MO638, which reacts with the terminal globular domain of the α5 chain) RESULTS: The majority of BCC cases showed patchy cytoplasmic distribution of laminin.
  • The BM expression of laminin, in most cases, was well defined, fine and linear with irregular areas of thickening.
  • CONCLUSION: Cytoplasmic and basement membrane laminin is important in the pathogenesis and invasion of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Laminin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Biopsy. Child. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Skin Aging. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 19615022.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin
  •  go-up   go-down


78. Arshad AR, Azman WS, Kreetharan A: Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck; 2008 Apr;30(4):544-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma.
  • Its association with basal cell carcinoma is well known.
  • METHOD: This is a case report of sebaceous carcinoma complicated by both basal cell carcinoma and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972311.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. So PL, Tang JY, Epstein EH: Novel investigational drugs for basal cell carcinoma. Expert Opin Investig Drugs; 2010 Sep;19(9):1099-112
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel investigational drugs for basal cell carcinoma.
  • IMPORTANCE OF THE FIELD: In the United States, the annual incidence of basal cell carcinoma (BCC) is close to 1 million.
  • Ultraviolet radiation exposure is the main risk factor; however, the availability of ever more potent sunscreens and education have not prevented the rise in BCC incidence.
  • AREAS COVERED IN THIS REVIEW: This article summarizes our current understanding of the etiology and molecular mechanisms of BCC tumorigenesis and discusses the preclinical and clinical studies to identify agents with anti-BCC efficacy.
  • WHAT THE READER WILL GAIN: The discovery that hyperactive Hh pathway signaling causes several cancers, including BCC, has spawned the development of many pharmacologic inhibitors of Hh signaling.
  • Early clinical testing of the most advanced, GDC-0449, demonstrated impressive efficacy in patients with advanced BCC.
  • Other promising anti-BCC chemopreventive strategies include drugs that are already FDA-approved for treating other diseases.
  • TAKE HOME MESSAGE: Preclinical and clinical trials with pre-existing FDA-approved drugs suggest novel uses for BCC chemoprevention and treatment.
  • Also, new chemical entities that inhibit the Hh pathway show promise, and in combination with other drugs may provide a nonsurgical cure for this most common cancer.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Drugs, Investigational / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10171-8 [17047082.001]
  • [Cites] PLoS Biol. 2006 Jul;4(8):e232 [16895439.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1770(3):467-77 [16963187.001]
  • [Cites] Mutat Res. 2007 Apr 1;617(1-2):138-46 [17307204.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3483-91 [17409458.001]
  • [Cites] J Am Acad Dermatol. 2007 May;56(5):781-5 [17261341.001]
  • [Cites] J Nutr Biochem. 2007 May;18(5):287-96 [17049833.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60 [17494766.001]
  • [Cites] Cancer Lett. 2007 Aug 8;253(1):53-9 [17321042.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2185-8 [17695502.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Nov 1;224(3):249-56 [17234230.001]
  • [Cites] Med Hypotheses. 2008;70(1):202-3 [17870251.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):249-60 [18328428.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1248-55 [18403589.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1275-84 [18483315.001]
  • [Cites] Clin Interv Aging. 2008;3(1):71-6 [18488880.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2022-32 [18645012.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2725-35 [18790753.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] Nutr Rev. 2008 Oct;66(10 Suppl 2):S116-24 [18844838.001]
  • [Cites] J Med Chem. 2008 Nov 13;51(21):6646-9 [18842035.001]
  • [Cites] Dev Cell. 2008 Dec;15(6):801-12 [19081070.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):9-18 [19124815.001]
  • [Cites] Oncol Rep. 2009 Mar;21(3):689-92 [19212627.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2623-8 [19196978.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3196-201 [19218434.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(13):2321-4 [19222062.001]
  • [Cites] Exp Oncol. 2009 Mar;31(1):9-15 [19300410.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):276-83 [19226541.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):310-21 [19336730.001]
  • [Cites] J Am Acad Dermatol. 2009 Jul;61(1):66-72 [19464071.001]
  • [Cites] Org Lett. 2009 Jul 2;11(13):2824-7 [19552464.001]
  • [Cites] Mar Drugs. 2009;7(2):153-65 [19597578.001]
  • [Cites] Bioorg Med Chem. 2009 Jul 15;17(14):4943-54 [19541490.001]
  • [Cites] J Med Chem. 2009 Jul 23;52(14):4400-18 [19522463.001]
  • [Cites] Expert Opin Ther Pat. 2009 Aug;19(8):1039-56 [19505195.001]
  • [Cites] PLoS One. 2009;4(8):e6593 [19672316.001]
  • [Cites] Cardiovasc Drugs Ther. 2009 Aug;23(4):261-2 [19618258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14132-7 [19666565.001]
  • [Cites] Nat Med. 2009 Sep;15(9):1055-61 [19701205.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:78-84 [19775361.001]
  • [Cites] J Dermatol Sci. 2009 Nov;56(2):76-81 [19781914.001]
  • [Cites] Science. 2009 Oct 23;326(5952):572-4 [19726788.001]
  • [Cites] J Dermatolog Treat. 2009;20(6):328-35 [19954388.001]
  • [Cites] Mol Biosyst. 2010 Jan;6(1):44-54 [20024066.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):8-11 [20051367.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):35-47 [20051371.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Feb;3(2):132-5 [20103730.001]
  • [Cites] Cancer Cell. 2010 Apr 13;17(4):388-99 [20385363.001]
  • [Cites] Anticancer Res. 2010 Mar;30(3):777-83 [20392996.001]
  • [Cites] J Invest Dermatol. 2010 May;130(5):1438-43 [20043012.001]
  • [Cites] Med Res Rev. 2011 Mar;31(2):161-201 [19967720.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Aug;15(8):868-71 [2754091.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12125-8 [8647801.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Mol Carcinog. 2009 May;48(5):408-19 [18781608.001]
  • [Cites] PLoS One. 2009;4(5):e5592 [19440351.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1966-7 [19411834.001]
  • [Cites] Trends Pharmacol Sci. 2009 Jun;30(6):303-12 [19443052.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3438-43 [10725363.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 2;280(4):1042-7 [11162632.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2001 Nov-Dec;14(6):358-62 [11598435.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Oncogene. 2001 Nov 22;20(53):7770-8 [11753655.001]
  • [Cites] Dermatol Surg. 2001 Dec;27(12):1035-8 [11849266.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4773-80 [12183437.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6 [12391318.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Australas J Dermatol. 2002 Nov;43(4):269-73 [12423433.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):151-6 [12582025.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21 [12679522.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3933-8 [14999099.001]
  • [Cites] J Clin Invest. 2004 Mar;113(6):867-75 [15067319.001]
  • [Cites] Skin Pharmacol Physiol. 2004 May-Jun;17(3):111-8 [15087589.001]
  • [Cites] J Invest Dermatol. 2004 Apr;122(4):1037-41 [15102095.001]
  • [Cites] Eur J Dermatol. 2004 Mar-Apr;14(2):96-102 [15196999.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4385-9 [15231643.001]
  • [Cites] Oncogene. 2004 Jul 8;23(31):5350-9 [15094780.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):148-56 [15270884.001]
  • [Cites] Cancer Lett. 2004 Nov 8;215(1):1-20 [15374627.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] Hum Mol Genet. 2004 Nov 1;13(21):2595-606 [15367491.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:138-44 [3480250.001]
  • [Cites] Int J Dermatol. 1987 Nov;26(9):606-9 [3443534.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85 [3165982.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Lett. 1997 Jun 24;116(2):197-203 [9215864.001]
  • [Cites] J Am Acad Dermatol. 1997 Aug;37(2 Pt 3):S12-7 [9270551.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] J Invest Dermatol. 1998 Oct;111(4):656-61 [9764849.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):833-6 [9989836.001]
  • [Cites] Exp Cell Res. 2004 Dec 10;301(2):189-200 [15530855.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):43-51 [15656799.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Eur J Cancer Prev. 2005 Oct;14(5):473-6 [16175052.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):187-97 [16459298.001]
  • [Cites] J Invest Dermatol. 2006 May;126(5):1143-51 [16528365.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] Int J Dermatol. 2006 May;45(5):489-98 [16700779.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):933-46; quiz 947-50 [16713450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8408-13 [16707575.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:197-204 [16869754.001]
  • [Cites] Exp Dermatol. 2006 Sep;15(9):742-50 [16881970.001]
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1917-22 [16679309.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9731-5 [17018632.001]
  • (PMID = 20662553.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR056736; United States / NIAMS NIH HHS / AR / K23 AR056736-03
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Drugs, Investigational; 0 / Hedgehog Proteins
  • [Other-IDs] NLM/ NIHMS298539; NLM/ PMC3775578
  •  go-up   go-down


80. Caresana G, Giardini R: Dermoscopy-guided surgery in basal cell carcinoma. J Eur Acad Dermatol Venereol; 2010 Dec;24(12):1395-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy-guided surgery in basal cell carcinoma.
  • BACKGROUND: In basal cell carcinoma (BCC), excision margins between 3 and 10 mm, according to site, size, borders, previous treatment and histology, can allow for radical excision in at least 95% of cases.
  • OBJECTIVE: The objective was to ascertain whether dermoscopy can detect more accurately the lateral borders in BCCs than clinical examination alone, and allow us to obtain radical excision in more than 95% of cases with only 2-mm excision margins.
  • METHODS: A prospective study was performed of 200 consecutive BCCs of the head and neck removed with 2-mm dermoscopically detected excision margins.
  • Morpheaform BCC, deeply recurrent BCC, BCC in Gorlin-Goltz syndrome, BCC located in sites not accessible through dermoscopy and superficial multifocal BCC were excluded.
  • All cases of excised BCC were submitted to a uniform method of histological examination of the whole specimen with serial parallel sections at 2-mm intervals.
  • RESULTS: In only three cases did surgical excision with 2-mm margins prove to be inadequate; in the remaining 197 cases, the excision margins were tumour-free.
  • The comparison of clinical and dermoscopic extension measurement showed concordance in 131 cases (65.5%).
  • In 69 cases (34.5%), dermoscopic evaluation showed a larger peripheral extension.
  • CONCLUSIONS: These results indicate that 2-mm dermoscopically detected excision margins can achieve histologically confirmed complete excisions in 98.5% of cases.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Dermoscopy. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20384678.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


81. Newman JC, Leffell DJ: Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg; 2007 Aug;33(8):957-64; discussion 965
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma.
  • BACKGROUND: The clinical relevance of the anatomic distribution of basal cell carcinoma is not completely understood.
  • Embryonic fusion planes--the regions of mesenchymal migration and fusion of the five primordial facial processes during the 5th to 10th weeks of human development--have been implicated in the pathogenesis of basal cell carcinoma.
  • OBJECTIVE: This study sought to examine the predilection of midfacial basal cell carcinoma for cutaneous anatomical sites correlated to embryonic fusion planes.
  • METHODS AND MATERIALS: Using archived digital images and a detailed anatomic diagram, cases of basal cell carcinoma were coded according to their specific location and were aggregated into two anatomic domains according to their correlation to embryonic fusion planes.
  • RESULTS: Of the 1,457 cases examined, 859 were located in the midface.
  • CONCLUSIONS: Although there is no consensus about the importance of anatomic location in the pathogenesis of basal cell carcinoma, these data indicate that, after adjusting for surface area, basal cell carcinoma was more than four times more likely to occur on an embryonic fusion plane than on other regions of the midface.
  • These data support the possibility of an embryologic role for the pathogenesis of basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / embryology. Carcinoma, Basal Cell / pathology. Facial Neoplasms / embryology. Facial Neoplasms / pathology. Skin Neoplasms / embryology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2008 Jun;34(6):851-3; author reply 853 [18384370.001]
  • (PMID = 17661939.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Smullen MJ, Bertler DE: Basal cell carcinoma of the sole: possible association with the shoe-fitting fluoroscope. WMJ; 2007 Aug;106(5):275-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the sole: possible association with the shoe-fitting fluoroscope.
  • Basal cell carcinoma of the sole is very rare.
  • This report describes an occurrence in which a basal cell carcinoma may have developed in relation to radiation exposure from a shoe-fitting fluoroscope.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Fluoroscopy / adverse effects. Foot Diseases / etiology. Neoplasms, Radiation-Induced. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874675.001).
  • [ISSN] 1098-1861
  • [Journal-full-title] WMJ : official publication of the State Medical Society of Wisconsin
  • [ISO-abbreviation] WMJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Bostock-Ling N: Excising basal cell carcinoma in general practice. Aust Fam Physician; 2006 Jul;35(7):558-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excising basal cell carcinoma in general practice.
  • BACKGROUND: Currently there is much interest in the general practice management of basal cell carcinoma (BCC).
  • METHODS: A retrospective audit of histopathology reports from 91 excisions of BCCs.
  • RESULTS: Thirty-nine percent of BCCs in this series were located on the head or neck, compared with 75-94% from other series; 50% of BCCs from the head/neck contained an aggressive histological subtype, compared with only 10% from other sites; four out of 139 papers found regarding surgical management of BCCs were from primary care practice.
  • DISCUSSION: Significant differences exist between the location mix and histological types of BCCs treated in general practice with those reported in the research literature.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Family Practice / statistics & numerical data. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820836.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


84. Lupi O: Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. Int J Dermatol; 2007 Nov;46(11):1113-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlations between the Sonic Hedgehog pathway and basal cell carcinoma.
  • The Sonic hedgehog (SHH) pathway is implicated in the etiology of the most common human cancer, the basal cell carcinoma (BCC).
  • Mutations in the receptor of SHH, the patched gene (PTCH), have been characterized in sporadic BCCs as well as those from patients with the rare genetic syndrome nevoid BCC.
  • Human PTCH is mutated in sporadic as well as hereditary BCCs, and inactivation of this gene is probably a necessary if not sufficient step for tumorigenesis.
  • Delineation of the biochemical pathway in which PTCH functions may lead to rational medical therapy for skin cancer and possibly other tumors.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Forkhead Transcription Factors / metabolism. Hedgehog Proteins / metabolism. Receptors, Cell Surface / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic. Humans. Mutation. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Signal Transduction. Veratrum Alkaloids / pharmacology

  • Genetics Home Reference. consumer health - PTCH1 gene.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988327.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SHH protein, human; 0 / SMO protein, human; 0 / Veratrum Alkaloids; 0 / patched receptors; ZH658AJ192 / cyclopamine
  • [Number-of-references] 35
  •  go-up   go-down


85. Jovanović M, Brasanac D, Rasulić L, Colić M, Stojicić M, Malis M: [The excision width in surgical treatment of basal cell carcinoma]. Acta Chir Iugosl; 2006;53(3):53-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The excision width in surgical treatment of basal cell carcinoma].
  • Basal cell carcinoma originates from pluripotent cells of basal layer of epiderm, external covering of hair follicles, sebaceous glands or other skin adnexa.
  • There are several types of basal cell carcinomas that may be manifested in over 12 clinical forms.
  • The analysis included 250 patients of both gender and different age, operated for basal cell carcinoma.
  • Clinical characteristics of basal cell carcinoma and the width of the excision were described.
  • It was concluded that the width of the excision of basal cell cancer was in relation to histological type.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338201.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


86. Chai L, Tang J: [Analysis of 41 cases of basal cell carcinoma in maxillofacial area]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr;20(7):297-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 41 cases of basal cell carcinoma in maxillofacial area].
  • OBJECTIVE: To explore the incidence, location and relationship between surgical margin and metastasis of basal cell carcinoma (BCC) in maxillofacial area.
  • METHOD: Retrospective study was undertaken of 41 cases of BCCs in the maxillofacial region diagnosed in histopathology during the period of 1996 to 2003.
  • RESULT: From 1996 to 2003, there were 41 cases of primary BBC in maxillofacial region, of whom 17 were males and 24 were females (male-to-female ratio, 1:1.41).
  • The age of BCCs patients was between 55-74 years old, the average age of female patients was 68.1 years old, and that of the male was 58.4 years old.
  • The lesions of BCCs were found in 13 cases in the nose (31.7%), 8 cases in scalp skin (19.5%), 7 cases in periorbital skin (17.1%), 7 cases in perioral region (17.1%), 4 cases in cheek skin (9.8%) and 2 cases in auricle skin (4.89%).
  • Of all the 41 patients, 4 patients were found to suffer regional lymph nodes metastasis or local bone destruction at the first visit (9.8%), 3 patients (7.3%) had a recurrent BCC.
  • [MeSH-major] Carcinoma, Basal Cell. Facial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780141.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


87. Gudi V, Ormerod AD, Dawn G, Green C, MacKie RM, Douglas WS, Gupta G, Scottish Dermatological Society: Management of basal cell carcinoma by surveyed dermatologists in Scotland. Clin Exp Dermatol; 2006 Sep;31(5):648-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of basal cell carcinoma by surveyed dermatologists in Scotland.
  • BACKGROUND: The British Association of Dermatologists (BAD) has produced guidelines for management of basal cell carcinoma (BCC) in the UK.
  • OBJECTIVES: Our primary objectives were to assess the management of BCCs in Scotland and to compare it with BAD guidelines.
  • METHODS: In phase I of the audit, dermatologists in 14 centres across Scotland prospectively registered demographic and clinical data of all lesions suspected to be BCCs over a 6-week period between October and December 2000.
  • In phase II, details of management of these lesions were evaluated by case note review.
  • There were 524 clinically suspected BCCs seen in 470 patients; 164 lesions in 146 patients showed pathology other than BCC and were excluded from analysis, thus leaving 360 lesions available for analysis.
  • BCCs were equally distributed between the sexes, and lesions most commonly presented in those aged 71-80 years.
  • A diagnostic biopsy was taken in 22% of lesions, and the rest were treated definitively after a clinical diagnosis of BCC, of which 90% were confirmed on histology.
  • Nodulocystic lesions were the most common type of tumour, comprising 48% of lesions, and most BCCs were located on the head and neck region.
  • Correlation of the histological type of BCC and treatment received showed that nodulocystic and morpheic BCCs were managed as recommended.
  • There were more superficial BCCs treated with surgical excision than expected (22 of 34 lesions).
  • CONCLUSIONS: In general, BCCs are managed according to BAD guidelines in Scotland, but waiting times vary considerably.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901303.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


88. Alessi E, Venegoni L, Fanoni D, Berti E: Cytokeratin profile in basal cell carcinoma. Am J Dermatopathol; 2008 Jun;30(3):249-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin profile in basal cell carcinoma.
  • Origin of basal cell carcinoma (BCC) is still unclear.
  • We studied the cytokeratin (CK) profile in BCC using monoclonal antibodies against 12 CKs to further investigate the suggested origin of the tumor from follicular matrix cells or from follicular outer root sheath cells and to determine if BCC subtypes can be identified on the basis of their CK profiles.
  • Cases of pilomatricoma and samples of fetal skin served as controls to establish the CK profile in matrical cells and developing follicles during intrauterine life, that of the epidermis and cutaneous adnexa in adult life having been determined in a previous study.
  • The most significant findings were as follows: (a) CK 5 and CK 17 positivity in all the BCCs studied;.
  • (b) CK 7, CK 8, CK 18, and CK 19 positivity in 30/52, 33/52, 42/52, and 14/52 BCCs, respectively;.
  • (c) CK 14 negativity in almost all the BCCs studied; and (d) lack of CK 1 expression only in 2/2 morpheiform BCCs and 4/10 nodular BCCs.
  • The study suggests a tumorous differentiation toward follicular outer root sheath cells and, in most cases, also toward the glandular components of the pilosebaceous-apocrine unit.
  • No significant difference in the CK profile among the BCC subtypes studied was found.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Cell Transformation, Neoplastic. Fetus. Gestational Age. Hair Diseases / metabolism. Hair Diseases / pathology. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Keratinocytes / metabolism. Keratinocytes / pathology. Pilomatrixoma / metabolism. Pilomatrixoma / pathology. Skin / chemistry. Skin / embryology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496426.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


89. Lin LK, Lee H, Chang E: Pigmented basal cell carcinoma of the eyelid in Hispanics. Clin Ophthalmol; 2008 Sep;2(3):641-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented basal cell carcinoma of the eyelid in Hispanics.
  • BACKGROUND: Pigmented basal cell carcinoma (PBCC) of the eyelid has not been well cited in the literature, and is often overlooked in the differential diagnosis of pigmented eyelid lesions.
  • METHODS: Retrospective review of patients with eyelid skin cancer who presented to the Department of Dermatology at the Keck School of Medicine of the University of Southern California and the Doheny Eye Institute from January 2002 to November 2005.
  • RESULTS: Sixty-nine of the 79 patients with eyelid skin cancer had basal cell carcinoma.
  • CONCLUSIONS: Although eyelid PBCC is regarded as a rare condition, it may occur more commonly in the Hispanic population and should be remembered in the differential diagnosis of pigmented eyelid lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1996 May;34(5 Pt 1):751-2 [8632068.001]
  • [Cites] J Am Acad Dermatol. 1991 Dec;25(6 Pt 1):1005-11 [1810978.001]
  • [Cites] J Dermatol Surg Oncol. 1984 Nov;10(11):876-81 [6491026.001]
  • [Cites] Cancer. 1982 Oct 1;50(7):1440-6 [7104982.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):528-36 [11568742.001]
  • [Cites] Arch Ophtalmol (Paris). 1976 Oct;36(10):633-44 [139864.001]
  • [Cites] Arch Dermatol. 1973 Feb;107(2):206-7 [4685577.001]
  • [Cites] J Dermatol Surg. 1975 Mar;1(1):28-32 [1223142.001]
  • [Cites] Br J Dermatol. 1975 Oct;93(4):361-70 [1201188.001]
  • [Cites] Am J Ophthalmol. 1981 Aug;92(2):193-7 [7270632.001]
  • [Cites] Arch Dermatol. 1960 Jan;81:95-102 [13832072.001]
  • (PMID = 19668766.001).
  • [ISSN] 1177-5467
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2694027
  • [Keywords] NOTNLM ; eyelid / lesions / pigmented basal cell carcinoma / skin cancer
  •  go-up   go-down


90. Izikson L, Bhan A, Zembowicz A: Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors. Am J Dermatopathol; 2005 Apr;27(2):91-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors.
  • Histologic differentiation between basal cell carcinoma and benign trichoblastic neoplasms such as trichoepithelioma and trichoblastoma can be difficult on small biopsies.
  • Recent studies have shown androgen receptor expression in a number of mature epithelial structures in the skin and in epithelial neoplasms including basal cell carcinoma.
  • These findings suggested that androgen receptor expression might be a useful adjunct in the histologic differential diagnosis between basal cell carcinoma and benign trichoblastic neoplasms.
  • Therefore, we performed immunohistochemical analysis of androgen receptor expression in 32 basal cell carcinomas and 10 benign trichoblastic tumors (6 trichoepitheliomas and 4 trichoblastomas).
  • In our study, at least focal expression of androgen receptor was detected in 78% of basal cell carcinomas.
  • These results confirm the lack of expression of androgen receptor in benign trichoblastic neoplasms and indicate that androgen receptor expression by tumor cells points to basal cell carcinoma as the most likely diagnosis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Hair Follicle / metabolism. Receptors, Androgen / biosynthesis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798431.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


91. Paavilainen V, Aaltonen M, Tuominen J, Saari KM: Histological characteristics of basal cell carcinoma of the eyelid. Ophthalmic Res; 2007;39(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological characteristics of basal cell carcinoma of the eyelid.
  • PURPOSE: To evaluate the histological subtypes of basal cell carcinoma (BCC) of the eyelid and to determine their effect on the size, depth of invasion and need of retreatment of a nonselected patient material seen in south-western Finland.
  • METHODS: We studied the case records and the histological characteristics of BCC of the eyelid treated at the Turku University Eye Clinic during the years 1988 through 1997.
  • The material consisted 103 patients (103 BCC tumors of the eyelid).
  • RESULTS: In 78.3% of the cases, the diameter of the lesion was smaller than 10 mm.
  • The most frequent histological subtype was nodular (84.5%) followed by sclerosing (5.8%), micronodular (4.9%), keratotic (2.9%) and superficial (1.9%) types of BCC of the eyelid.
  • Only patients of the nodular subtype showed recurrences (11 cases).
  • However, some nodular types of BCC tumors smaller than 10 mm in diameter extended to a depth of more than 4.0 mm.
  • CONCLUSIONS: The nodular subtype of BCC should be regarded as a potentially invasive and recurrent tumor.
  • Histopathological examination and subtyping of all BCC tumors is recommended.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164577.001).
  • [ISSN] 0030-3747
  • [Journal-full-title] Ophthalmic research
  • [ISO-abbreviation] Ophthalmic Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


92. Del Sordo R, Cavaliere A, Sidoni A: Basal cell carcinoma with matrical differentiation: expression of beta-catenin [corrected] and osteopontin. Am J Dermatopathol; 2007 Oct;29(5):470-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with matrical differentiation: expression of beta-catenin [corrected] and osteopontin.
  • Basal cell carcinoma with matrical differentiation is an extremely rare variant.
  • To date, only 12 cases have been described in the literature.
  • This tumor is a typical basal cell carcinoma with basaloid nests containing shadow cells identical to those of pilomatricoma and pilomatrical carcinoma.
  • We present two additional cases and have investigated the immunoprofile of .
  • The morphological and immunohistochemical features of these cases that we have found suggest that basal cell carcinomas with matrical differentiation belong to a spectrum of lesions deriving from hair follicles in which .
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Cell Transformation, Neoplastic / pathology. Osteopontin / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Dermatopathol. 2008 Jun;30(3):317
  • (PMID = 17890917.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta Catenin; 106441-73-0 / Osteopontin
  •  go-up   go-down


93. Gambichler T, Skrygan M, Hyun J, Bechara F, Tomi NS, Altmeyer P, Kreuter A: Cytokine mRNA expression in basal cell carcinoma. Arch Dermatol Res; 2006 Aug;298(3):139-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine mRNA expression in basal cell carcinoma.
  • There is evidence that cytokines (CKs) play a significant role in the development and/or progression of skin cancer.
  • The aim of the present study was to investigate the mRNA expression of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-8 in biopsy specimens of basal cell carcinoma (BCC), and to compare the results with the mRNA levels of non-lesional skin of BCC patients and healthy subjects.
  • Skin samples were obtained from 22 patients with BCC (lesional, non-lesional) and 25 healthy subjects (controls).
  • Histological examination revealed 12 nodular BCCs and 10 superficial BCCs.
  • The mRNA levels of CKs observed in healthy controls did not significantly (P > 0.05) differ from non-lesional CK levels of BCCs patients.
  • However, IL-6 and IL-8 levels of lesional skin were significantly (P < 0.05) higher than the CK levels observed in non-lesional skin and controls, respectively. mRNA expression of IL-6 and IL-8 showed a significant positive correlation (r = 0.51; P < 0.05).
  • There was no significant (P > 0.05) difference between lesional mRNA levels of TNF-alpha and those levels observed in non-lesional skin and controls.
  • The mRNA expression of CKs found in nodular and superficial BCCs did not significantly differ (P > 0.05).
  • BCC is associated with a significant increase of IL-6 and IL-8 expression.
  • In accordance with previous studies our data suggest a role for IL-6 and IL-8 in the development and/or progression of BCC, since mRNA expression of both CKs are significantly increased in tumour tissue.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Cytokines / genetics. RNA, Messenger / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826314.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger
  •  go-up   go-down


94. Babaye-Nazhad S, Amirnia M, Alikhah H, Khodaeyani E, Atapour N: Safety margin in excision of basal cell carcinoma. Pak J Biol Sci; 2009 Nov 1;12(21):1408-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety margin in excision of basal cell carcinoma.
  • Fifty patients with basal cell carcinoma operated in Tabriz Sina hospital, were chosen randomly and pathological report of these patients after surgery was evaluated with consideration of presence of intact margin.
  • In pathologic report before operation of these patients, Basal cell carcinoma was certified.
  • Also, brief data of these patients history was studied from present cases.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20128511.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


95. Fan YS, Carr RA, Sanders DS, Smith AP, Lazar AJ, Calonje E: Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma. Histopathology; 2007 Jul;51(1):80-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma.
  • AIMS: There is considerable overlap between the histological features of sebaceoma and basal cell carcinoma (BCC).
  • The distinction between these two tumours is important due to the often more locally aggressive nature of BCC and the association of sebaceoma with the Muir-Torre syndrome.
  • The aim of this study was to describe the immunohistochemical reactivity of the cells in sebaceoma to Ber-EP4 and epithelial membrane antigen (EMA) and investigate the utility of this panel to differentiate sebaceoma from basal cell carcinoma.
  • A single case exhibited focal weak Ber-EP4 staining, predominantly in mature sebocytes and in < 10% of the tumour cells.
  • EMA was not expressed in the germinative cells of sebaceoma, but was expressed strongly in approximately 50% of mature sebocytes in all cases and highlighted the cytoplasmic vacuoles.
  • We reviewed the immunoreactivity of 51 cases of nodular BCCs and found moderate or strong BerEP4 expression in all cases with never less than 20% of the tumour staining.
  • Expression of EMA was uncommon in BCC (moderate or strong in 8%) and was confined to keratotic or squamoid areas.
  • CONCLUSION: The use of Ber-EP4 in combination with EMA, both widely used immunomarkers in histopathology, is a helpful aid in distinguishing sebaceoma from nodular BCC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Mucin-1 / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Sebaceous Glands / metabolism. Sebaceous Glands / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593083.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / human epithelial antigen-125
  •  go-up   go-down


96. Mosterd K, Arits AH, Thissen MR, Kelleners-Smeets NW: Histology-based treatment of basal cell carcinoma. Acta Derm Venereol; 2009;89(5):454-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology-based treatment of basal cell carcinoma.
  • Basal cell carcinoma is the most common type of skin cancer and its incidence is still rising.
  • Selection criteria were histological subtype, primary or recurrent basal cell carcinoma and tumour localization.
  • Although surgery remains the preferred treatment for most basal cell carcinomas, patient and tumour characteristics should be taken into account when choosing the most suitable treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Cryotherapy. Mohs Surgery. Photochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Evidence-Based Medicine. Humans. Neoplasm Invasiveness. Patient Selection. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Derm Venereol. 2009;89(5):450-2 [19734965.001]
  • [ErratumIn] Acta Derm Venereol. 2009 Nov;89(6):667
  • (PMID = 19734968.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


97. Aguayo-Leiva IR, Ríos-Buceta L, Jaén-Olasolo P: [Surgical vs nonsurgical treatment of basal cell carcinoma]. Actas Dermosifiliogr; 2010 Oct;101(8):683-92
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical vs nonsurgical treatment of basal cell carcinoma].
  • [Transliterated title] Tratamiento quirúrgico vs. no quirúrgico en el carcinoma basocelular.
  • Numerous therapeutic options are now available for the treatment of basal cell carcinoma.
  • Then, based on the evidence reviewed, we attempt to provide an outline of the therapeutic strategies recommended in basal cell carcinoma, and the approach to be used in specific situations.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cryosurgery. Fluorouracil / therapeutic use. Follow-Up Studies. Hedgehog Proteins / antagonists & inhibitors. Humans. Interferons / therapeutic use. Laser Therapy. Mohs Surgery. Neoplasm Recurrence, Local. Photochemotherapy. Phytotherapy. Plant Preparations / therapeutic use. Risk Factors. Semecarpus. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Actas Dermosifiliogr. 2011 Oct;102(8):633-4 [21798484.001]
  • (PMID = 20965011.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / Plant Preparations; 0 / SHH protein, human; 9008-11-1 / Interferons; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


98. Kostalevskaia AV, Petrunin DD, Romadanova NB, Snarskaia ES, Pal'tsev MA, Suchkov SV: [The current concept of immunological disorders in the case of basal-cell carcinoma]. Arkh Patol; 2008 Sep-Oct;70(5):42-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The current concept of immunological disorders in the case of basal-cell carcinoma].
  • Imbalance in the interaction of mechanisms of innate and adaptive immunity rather than selective defect of each of the links is a determinant of the development of basal-cell carcinoma of this or that form of immunopathology or that of transformation of one to another form.
  • The major tumor-associated immunological phenotypes are pathogenetically and clinically different, but have signs of two-link immunodeficiency in each case.
  • Predominant are autoimmune disorders involving mainly the adaptive link of immunological responsiveness in case of tumor-associated autoimmune syndrome concurrent with immunodeficiency.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. Immunologic Deficiency Syndromes / etiology. Skin Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19137785.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


99. Salas-Garcia I, Fanjul-Velez F, Ortega-Quijano N, Arce-Diego JL: Photodynamic effects on basal cell carcinoma with topical Photosensitizer. Conf Proc IEEE Eng Med Biol Soc; 2010;2010:2739-42
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic effects on basal cell carcinoma with topical Photosensitizer.
  • Photodynamic therapy (PDT) is a potential cancer therapy used in several clinical fields.
  • However, some cases of basal cell carcinoma show tumour persistence.
  • The poor response observed in this type of pathology, whose lesions penetrate in the deeper layers of the skin, could be attributed to an insufficient accumulation of the PS (Photosensitizer) in deeper tissues.
  • The development of accurate models could propose the adequate treatment dosimetry for those problematic cases in order to maximize the efficiency of the PDT treatment outcome.
  • In this work we present a PDT model that tries to predict the photodynamic effect on the skin affected by a basal cell carcinoma with a topically administered photosensitizer.
  • The results obtained allow us to know the evolution of the cytotoxic agent in order to estimate the necrotic area adjusting parameters such as the optical power, the photosensitizer concentration, the incubation and exposition time or the diffusivity and permeability of the damaged tissue.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Photochemotherapy / methods. Photosensitizing Agents / pharmacology. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21096212.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; S88TT14065 / Oxygen
  •  go-up   go-down


100. Asgari MM, Tang J, Epstein EH Jr, Chren MM, Warton EM, Quesenberry CP Jr, Go AS, Friedman GD: Statin use and risk of basal cell carcinoma. J Am Acad Dermatol; 2009 Jul;61(1):66-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statin use and risk of basal cell carcinoma.
  • OBJECTIVE: We examined the association between statin use and basal cell carcinoma (BCC) risk.
  • METHODS: We identified all members of a large integrated health care delivery system with a diagnosis of a histologically proven BCC in 1997.
  • Subsequent BCCs were identified through 2006 from health plan electronic pathology records.
  • We used extended Cox regression to examine the independent association between receipt of statin therapy (ever vs never, cumulative duration) and risk of subsequent BCC.
  • RESULTS: Among 12,123 members given a diagnosis of BCC who had no prior statin exposure, 6381 developed a subsequent BCC during follow-up.
  • Neither "ever use of statins" (adjusted hazard ratio 1.02, 95% confidence interval: 0.92-1.12) or cumulative duration of statin (adjusted hazard ratio 1.02/year, 95% confidence interval: 0.99-1.11) was associated with subsequent BCC after adjustment for age, sex, and health care use.
  • There was also no significant association between use of non-statin antilipemics and subsequent BCC (adjusted hazard ratio 1.10, 95% confidence interval: 0.76-1.58).
  • LIMITATIONS: No information was available for BCC risk factors, such as sun sensitivity and sun exposure.
  • CONCLUSIONS: Among a large cohort of individuals with BCC, statin therapy was not significantly associated with risk of subsequent BCC.

  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] Am J Med. 2001 Jun 15;110(9):716-23 [11403756.001]
  • [Cites] Circulation. 2002 May 21;105(20):2341-6 [12021218.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):10-9 [12538446.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4808-17 [17001070.001]
  • [Cites] JAMA. 2006 Nov 1;296(17):2105-11 [17077375.001]
  • [Cites] N Engl J Med. 2007 Oct 11;357(15):1477-86 [17928595.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Nov 1;224(3):257-64 [17276471.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36 [17944002.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 [18182618.001]
  • [Cites] Am J Epidemiol. 2008 Feb 15;167(4):492-9 [18056625.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1357-66 [18765432.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1343-56 [18765433.001]
  • [Cites] Int J Epidemiol. 2009 Feb;38(1):38-47 [18326513.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):425-9 [12637924.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 16;320(1):165-9 [15207716.001]
  • [Cites] Atherosclerosis. 2004 Aug;175(2):305-13 [15262187.001]
  • [Cites] JAMA. 1992 Jun 24;267(24):3305-10 [1597912.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Mol Carcinog. 1995 Apr;12(4):205-12 [7727042.001]
  • [Cites] Biochem J. 1995 Aug 15;310 ( Pt 1):305-9 [7646460.001]
  • [Cites] JAMA. 1996 Jan 3;275(1):55-60 [8531288.001]
  • [Cites] JAMA. 1998 May 27;279(20):1615-22 [9613910.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8408-13 [16707575.001]
  • [Cites] Free Radic Biol Med. 2006 Jul 15;41(2):339-46 [16814115.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):1082-4 [16924075.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1524-30 [11115165.001]
  • (PMID = 19464071.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / K24 AR052667; United States / NCI NIH HHS / CA / R01 CA 098838; United States / NIAMS NIH HHS / AR / K23 AR 051037; United States / NIAMS NIH HHS / AR / K23 AR051037-04; United States / NCI NIH HHS / CA / R01 CA098838; United States / NIAMS NIH HHS / AR / K23 AR051037; United States / NCI NIH HHS / CA / CA098838-04; United States / NIAMS NIH HHS / AR / K24 AR052667-04; United States / NIAMS NIH HHS / AR / AR052667-04; United States / NCI NIH HHS / CA / R01 CA098838-04; United States / NIAMS NIH HHS / AR / K24 AR 052667; United States / NIAMS NIH HHS / AR / AR051037-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • [Other-IDs] NLM/ NIHMS99847; NLM/ PMC2700205
  •  go-up   go-down






Advertisement